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The bacterial cell wall is a complex structure essential for life. The primary structural component of the wall for 
most bacteria, including the major human pathogen Staphylococcus aureus, is peptidoglycan. As peptidoglycan 
is unique to bacteria its synthesis forms the target for some of the most important clinically used antibiotics. 
The spread of antibiotic resistance is a global healthcare challenge. Addressing this massive problem requires a 
multifaceted approach ranging from reducing antibiotic use, to the discovery of new antibiotic interventions 
and alternatives. 
The β-lactam and glycopeptide groups of antibiotics that target cell wall synthesis, exemplified by methicillin 
and vancomycin respectively, are some of the most commonly used antibiotics to treat S. aureus infections. 
The molecular pathway to bacterial cell death after treatment of S. aureus with these compounds is not well 
understood even after decades of clinical efficacy. To elucidate the bactericidal mechanism of methicillin and 
vancomycin, an integrated range of approaches was taken.  
Characteristically, methicillin treatment initially shows a small increase in cell numbers prior to a decrease due 
to the action of the antibiotic, whereas vancomycin kills more slowly but without the initial increase. 
Structured illumination microscopy (SIM) demonstrated that both vancomycin and methicillin led to a 
significant cell volume increase prior to death in the absence of any peptidoglycan synthesis. Electron 
microscopy revealed that only with methicillin were bulbous septa apparent. Methicillin-treated cells still 
divided if they had a complete septum upon antibiotic addition whereas vancomycin treated cells did not. This 
difference was likely due to the action of peptidoglycan hydrolases at the presumptive septum. 
A new model of the action of antibiotics was derived from this research. In combination with other data 
derived during the time of my PhD, this has led to an overarching theory as to how bacteria can grow and the 
activity of cell wall antibiotics. Utilisation of this data provides novel avenues for the use of existing antibiotics 
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1.1. Staphylococcus aureus 
 
Staphylococcus aureus is a non-motile, gram-positive, spheroid bacterium approximately 1 µm in size. It is an 
opportunistic pathogen that can also live as a commensal organism. In humans, S. aureus is found in the 
anterior nares (Stapleton & Taylor, 2002), where approximately 20% of the population are permanent carriers 
of S. aureus, and 60% are intermittent carriers (Kluytmans, 1997). S. aureus opportunist infections are 
classified into two categories: community-acquired (CA) and hospital-acquired (HA), including endocarditis, 
pneumonia, toxic shock syndrome, mastitis and skin infections (Boucher & Corey, 2008).  
Due to its opportunistic nature, patients with HIV, cancer, type I diabetes, surgical patients and intravenous 
drug users are at higher risk of developing S. aureus infections (Lowy, 1998).  S. aureus bacteraemia has a case 
fatality rate of between 15 to 50%, with an incidence ranging from 10 to 30/100000 people per year in 
industrialised countries (Tong et al., 2015). S. aureus is the leading cause of skin and soft tissue infections 
(SSTIs), infective endocarditis (IE) and joint infections. The mortality rate for IE caused by S. aureus is between 
22 and 66% (Tong et al., 2015). S. aureus can also cause pneumonia, particularly in hospitalised patients, 
accounting for >40% of health care-associated pneumonia cases in the US (Tong et al., 2015). S. aureus 
pneumonia infections often occur in patients with comorbid illnesses leading to poor prognosis. It is also 
associated with pneumonia infections in patients with influenza. For example, half the patients hospitalised 
with influenza A H1N1 in France during the 2009 pandemic had a bacterial coinfection. 31% of those 
coinfections were caused by S. aureus (Cuquemelle et al., 2011). These infections are associated with the 
cytotoxin Panton-Valentine leucocidin (PVL), which enhances virulence (Gillet et al., 2007).  
S. aureus is most renowned for its antibiotic resistance, with Methicillin-Resistant S. aureus (MRSA) and more 
recently Vancomycin-Resistant S. aureus (VRSA) as major health-care threats. In 2017/2018 Public Health 
England reported 12,784 S. aureus infections in England, which is a 3.7% increase from 2016/17. 6.6.% of the 
reported infections were caused by MRSA. 
1.2. Cell Wall 
 
The bacterial kingdom is divided into two main categories according to their cell wall structure. These two 
categories can be differentiated through gram-staining and are classified as gram-positive (cells are stained) or 





Gram-negative cell walls are made up of three distinct layers: the outer-membrane (OM), the peptidoglycan 
cell wall and the inner membrane (IM) (Figure 1.1). The space between the inner membrane and the outer-
membrane, within which the peptidoglycan cell wall is localised, is called the periplasm (Silhavy et al., 2010). 
Both the OM and the IM are lipid bilayers with differing compositions. The inner leaflet of the OM is composed 
of phospholipids and the outer leaflet is composed of glycolipids, mainly lipopolysaccharides (LPS). The IM is a 
phospholipid bilayer (Silhavy et al., 2010). The peptidoglycan layer found in the periplasm serves as an 
exoskeleton responsible for maintenance of cell shape. In gram-negatives, the peptidoglycan layer is 2-6 nm 
thick (Vollmer & Seligman, 2010). The periplasm plays a wide range of roles in cell metabolism from protein 
transport, to turgor pressure maintenance and cell signalling.  
1.2.2. Gram-positive 
 
Gram-positive bacteria have a cytoplasm containing phospholipid bilayer encapsulated within a thick outer-
layer of peptidoglycan (Silhavy et al., 2010) (Figure 1.1). Gram-positive organisms do not have an outer 
membrane and have a peptidoglycan layer 20-35 nm thick (Schleifer & Kandler, 1972). The gram-positive cell 
wall contains teichoic acids, which are long anionic polymers. There are two types of teichoic acids: wall 
teichoic acids (WTA) and lipoteichoic acids (LTA). WTA are anchored in the peptidoglycan and LTA are 
anchored in the cell membrane (Silhavy et al., 2010). The cell surface in gram-positives is also decorated with a 
range of proteins.  
Since there is only one lipid bilayer in gram-positive organisms, there is no equivalent to the periplasm present 
in gram-negative organisms. There is however a space between the lipid bilayer and the peptidoglycan layer: 
the gram-positive periplasm. Due to its location completely exterior to the cytoplasm and cell membrane, it 
will be referred to as the exoplasm in this thesis. A gram-positive periplasm, or exoplasm, was first proposed in 
S. aureus in the 1980s (Umeda, et al., 1987). Through separation of cell fractions an exoplasm in B. subtilis was 
hypothesised in 1995 (Merchante et al., 1995). B. subtilis and S. aureus exoplasms were later confirmed using 
cryo-transmission electron microscopy (Cryo-TEM) (Matias & Beveridge, 2005; Matias & Beveridge, 2006).  
Wall teichoic acids are composed of a disaccharide unit and a polyribitol phosphate (RboP) or polyglycerol 
phosphate (GroP) chain (Silhavy et al., 2010). RboP and GroP chains vary in length and can be up to 60 repeats 
long. WTA are anchored in the peptidoglycan layer via a phosphodiester linkage to the C6-hydroxyl of N-
acetylmuramic acid (MurNAc) residues. WTA are decorated with ᴅ-alanyl esters and/or monosaccharides, 
modifying their properties and function. WTA are involved in cation homeostasis, autolysin regulation and 
presentation of envelope proteins among other roles (Neuhaus & Baddiley, 2003). WTA can be modified 




Figure 1.1. Overview of the gram-positive and gram-negative cell envelopes. WTA – wall teichoic acid; CAP – 
covalently attached protein; LTA – lipoteichoic acid; IMP – inner membrane protein; LPS – lipopolysaccharide; 




charge of WTA by introducing positively charged amines. The level of D-alanylation varies according to 
environmental factors including growth media pH, NaCl concentration and temperature (Neuhaus & Baddiley, 
2003).  
The role of WTA in the cell is not fully understood but some of its roles in the cell wall metabolism are 
discussed here. The absence of WTA leads to a decrease in peptidoglycan crosslinking due to interactions with 
the peptidoglycan metabolism (Atilano et al., 2010). A decrease in crosslinking leads to an increased 
susceptibility to hydrolysis. The lack of D-alanylation also leads to increased sensitivity to glycopeptides and 
lytic activity of some host enzymes. WTAs therefore play an important role in protecting peptidoglycan from 
hydrolysis. 
Lipoteichoic acids are anchored in the cell membrane and do not extend beyond the peptidoglycan outer 
layer. LTA are composed of a glycolipid anchor and a GroP chain (Percy et al., 2014). Like WTA, the GroP chain 
of LTA is often modified with ᴅ-alanyl or glycosyl groups. In S. aureus every 9th lipid in the outer leaflet of the 
cell membrane is LTA (Koch et al., 1984). On average, S. aureus LTA are 25 GroP units long. LTA and WTA are 
crucial for the maintenance of a negative charge from the cell membrane through to the outer surface of the 
peptidoglycan layer. The crucial role teichoic acids play in maintenance of cell viability is demonstrated by the 
fact that, although neither WTA nor LTA are essential on their own, cells cannot survive without any teichoic 
acids (Silhavy et al., 2010).  
1.3. Peptidoglycan chemical structure 
 
Peptidoglycan is composed of a sugar backbone cross-linked by peptide side chains (Figure 1.2). The backbone 
is a chain of alternating N-acetlylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) linked via a β-1-4-
glycosidic bond (Vollmer, 2008). The composition of the glycan strand is maintained between species. There 
are however major variations in the length of glycan strands found in different bacteria. S. aureus is known to 
have particularly short glycan strands due to high glucosaminidase activity. Glucosaminidases are a class of 
peptidoglycan hydrolases that cleave the peptidoglycan sugar backbone. The average glycan chain in S. aureus 
is 6 disaccharides long (Boneca, et al., 2000). In contrast, B. subtilis peptidoglycan contains glycan chains up to 
5000 disaccharides long (Hayhurst et al., 2008). 
Glycan strands can undergo different secondary modifications such as N-deacetylation, N-glycolylation and O-
acetylation (Vollmer, 2008). Both GlcNAc and MurNAc can be deacetylated by peptidoglycan deacetylases 
giving GlcN and MurN. Deacetylation of peptidoglycan leads to decrease sensitivity to the muramidase 
lysozyme (Araki et al., 1971). Lysozyme is part of the human immune response, therefore N-deacetylation of 
the glycan strand will aid in infection of a host. O-acetylation also protects cells from the action of lysozyme. O-




Figure 1.2. S. aureus peptidoglycan chemical structure. Representation of a disaccharide with an attached 




glycolylation involves the modification of MurNAc, with a change of its acetate group into a glycolyl group. The 
biological role of N-glycolylation is not well understood. It has been hypothesised that it plays a role in cell 
envelope stability (Vollmer, 2008). 
Each MurNAc residue in peptidoglycan has its ᴅ-lactoyl group substituted by a peptide side chain. Peptide side 
chains exhibit a great amount of variability between organisms. The most common peptide side chain 
composition is ʟ-Ala-γ-ᴅ-Glu-meso-DAP-ᴅ-Ala-ᴅ-Ala (Bouhss et al., 2008). The third amino acid is the most 
variable, it is often ʟ-lysine in gram-positive organisms although other di- or mono-amino acids can also be 
found in this position (Vollmer et al., 2008). The last ᴅ-Ala residue is often lost in mature peptidoglycan or 
altered. Substitution of the terminal ᴅ-Ala with ᴅ-lactate or ᴅ-Ser confers vancomycin resistance (Courvalin, 
2006; Vollmer et al., 2008). The peptide side chains are most commonly crosslinked by forming a bond 
between the third amino acid of one chain and the 4th amino acid of another chain. Crosslinks can also be 
indirect, through amino acid bridges ranging from one to seven residues long (Schleifer & Kandler, 1972; 
Vollmer et al., 2008). S. aureus has particularly high levels of crosslinking in its peptidoglycan (70-80%) mainly 
due to PBP4 activity (Snowden & Perkins, 1990). Peptide side chains act as anchors for many surface proteins. 
1.4. Peptidoglycan architecture 
 
Despite our in depth understanding of peptidoglycan chemical structure, there are still many gaps in our 
understanding of peptidoglycan architecture and synthesis. Studies of peptidoglycan architecture have 
overwhelmingly been carried out using purified sacculi. Sacculi were imaged by electron microscopy (EM), 
electron cryo tomography (ECT) and atomic force microscopy (AFM) allowing for the proposal of several 
different architectural models. 
1.4.1. Models of glycan chain organisation 
 
Two models of glycan chain organisation have been proposed: the planar model and the scaffold model 
(Figure 1.3, panel C). In the planar model the glycan chains run parallel to the cell membrane and the short axis 
of the cell (Koch, 1998a). This orientation of glycan chains is supported by the fact that rod-shaped sacculi 
have greater elasticity in the direction of the long axis of the cell than in the direction of the short axis of the 
cell (Yao et al., 1999). The difference in elasticity is due to the peptide side chains having greater flexibility than 
the sugar backbone (Vollmer & Höltje, 2004). It was originally hypothesised that the glycan strands formed 
elongated straight helixes from which the peptide side chains extended perpendicularly to each other (Vollmer 
& Höltje, 2004) (Figure 1.3, Panel A). In Koch’s updated model, glycan strands are arranged in a zigzag pattern 
(Koch, 1998b). The peptide side chains in the same plane are crosslinked and the smallest, hexagonal holes 
formed in this structure are named tessera (Figure 1.3, Panel B). When evenly distributed across the cell wall, 




Figure 1.3. Models of glycan chains organisation. Dark grey/black bars represent MurNAc residues and light 
grey bars represent GlcNAc. (A) Representation of a helical glycan strand with peptide side chains (arrows) 
perpendicular to each other. Every other peptide side chain is in the same plane. (B) Representation of 
crosslinked zigzag glycan strands forming a tessera. (C)  Representation of the scaffold and planar models of 




being shorter than the circumference of the cell and crosslinking percentages being lower than 50% in some 
organisms, larger holes would exist in the peptidoglycan layer based on this model (Koch, 1998). These would 
be made up of fused tessera (smaller hexagonal holes). In gram-negative organisms, the cell wall is thought to 
be made up of one stress bearing layer of peptidoglycan with unloaded newly synthesised peptidoglycan on 
the inside and old, hydrolysed material on the outside. The gram-positive cell wall is proposed to consist of 
several linked layers of planar peptidoglycan (Vollmer & Höltje, 2004).  
The scaffold model of peptidoglycan strucutre proposes that the glycan strands run perpandicular to the 
cytoplasmic membrane with the cross-linked peptides side chains parallel to the cell membrane (Dmitriev et 
al., 2004; Dmitriev et al., 1999; Dmitriev et al., 2003) (Figure 1.3, Panel C). Several different problems arise 
with this model. Through knowledge of the average glycan chain length and the amount of cell wall material 
present in a cell, it has been argued that there is not enough peptidoglycan in an E. coli cell to cover the entire 
cell surface if it were arranged in a scaffold structure (Vollmer & Höltje, 2004). Additionaly, the peptidoglycan 
layer in E. coli is thought to be between 2.5 and 7 nm thick and to achieve this thickness in the scaffold model, 
glycan chains would need to be 2.5 to 7 disaccharides long. This is at odds with an average glycan chain length 
of 25-30 nm (Vollmer & Höltje, 2004).  
1.4.2. Peptidoglycan architecture in gram-negative bacteria 
 
Gram-negative bacteria have a thin peptidoglycan layer located in the periplasm. It is easier to study cell wall 
structure using this thin cell wall than using the thick gram-positive cell wall (Turner et al., 2014). ECT studies 
of E. coli and C. crescentus revealed a single layer of peptidoglycan making up the cell wall (Gan et al., 2008). 
Tubular structures, thought to be glycan strands due to their length, were observed along the plane of the 
sacculus and approximately parallel to the short axis of the cell (Gan et al., 2008). This data supports the planar 
model of glycan chain organisation. The pattern observed by ECT appeared uniform across the entire sacculi 
but the observed tubes were not regularly spaced or running exactly parallel to each other (Gan et al., 2008).  
More recent work on gram-negative peptidoglycan architecture was carried out using AFM (Turner et al., 
2013; Turner et al., 2018). AFM images confirmed the presence of peptidoglycan features running in the plane 
of the sacculi. Large bands (too wide to be glycan strands) were observed perpendicular to the long axis of the 
cell (Figure 1.4) (Turner et al., 2013). These bands appeared to be formed by more loosely or densely packed 
mesh. More recent, higher resolution AFM shows circumferential orientational order of long glycan chains in 
rod-shaped E. coli (Turner et al., 2018). Pores in this mesh were too big to fit the tessera model (Koch, 1998; 
Turner et al., 2013). The presence of these different bands also leads to a non-uniform thickness of 
peptidoglycan across the sacculus. Using this information, a new model of peptidoglycan insertion was 
proposed, whereby new peptidoglycan is inserted in the most porous regions. In this model, growth by 




Figure 1.4. Models of peptidoglycan architecture in B. subtilis, S. aureus and E. coli. Adapted from (Turner et 
al., 2014).  
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generated, and their peptidoglycan studied. Results showed that cells had shorter glycan chains that showed 
reduced orientational order, confirming that glycan chain length and organisation impact cell shape (Turner et 
al., 2018). 
1.4.3. Peptidoglycan architecture in gram-positive bacteria 
 
Gram-positive organisms have thicker peptidoglycan layers than gram-negative bacteria. Due its thickness, the 
gram-positive cell wall is thought to be composed of several layers of peptidoglycan, complicating architectural 
studies. Proposed peptidoglycan architectures for different gram-positive cell shapes are discussed below. 
1.4.3.1. Peptidoglycan architecture of gram-positive rods 
 
B. subtilis is the most studied gram-positive rod and has served as the main model for their peptidoglycan 
architecture. B. subtilis has exceptionally long glycan chains, with strands up to 5000 disaccharides long 
(Hayhurst et al., 2008). Extremely long glycan chains do not fit the scaffold cell wall architecture model where 
glycans are oriented perpendicular to the cell membrane. AFM was carried out on B. subtilis sacculi to help 
understand glycan strand organisation (Hayhurst et al., 2008). AFM revealed a rough exterior of the cell wall 
and cable structures on the inside of the cell wall. Previous EM data revealed striations running perpendicular 
to the short axis of the cell thought to be glycan strands (Verwer & Nanninga, 1976). The wide cable structures 
were interpreted as coils of several glycan strands, allowing for packaging of the long chains present in B. 
subtilis (Hayhurst et al., 2008). The lack of tubular structures visible on the outside of the cell wall is thought to 
be due to it consisting of older, more hydrolysed material. 
Using ECT to study B. subtilis peptidoglycan architecture, Beeby et al. did not identify cable structures in the 
cell wall (Beeby et al., 2013). Peptidoglycan appeared to be uniformly dense having a smooth inner surface. A 
gram-negative-like model was proposed with inside-to-outside peptidoglycan synthesis (Beeby et al., 2013). 
ECT has a high signal to noise ratio, which hinders visualisation of internal structures and is a major limitation 
of this technique (Turner et al., 2014). The proposed model does not consider previous AFM data. Further 
structural studies are required to better develop our understanding of B. subtilis cell wall architecture.  
1.4.3.2. Peptidoglycan architecture of gram-positive ovococci 
 
Ovococci have an elongated cell shape compared to cocci bacteria. S. pneumoniae, Lactococcus lactis and 
Enterococcus faecalis have been used to investigate cell wall architecture in ovococci (Wheeler et al., 2011). 
Ovococci have long glycan chains with 44-57% being > 50 disaccharides long (Wheeler et al., 2011). This is 
close to the 53% of glycan chains over 50 disaccharides long in B. subtilis compared to only 14% in S. aureus. 
These results do not fit with a scaffold model of peptidoglycan organisation. Using AFM of sacculi, glycan 
strands were found to be orientated parallel to the short axis of the cell and the cell membrane (as seen in 
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rods). The exterior of the cell wall was smooth, unlike the knobbly and rough surfaces observed in rods and 
cocci (1.4.3.1, 1.4.3.3). Annular features thought to be associated with growth and division were revealed. 
Differences have been observed between the different cocci. E. faecalis and L. lactis had a single growth 
annulus, whereas S. pneumoniae appeared to have three (Wheeler et al., 2011). These differences were 
attributed to differences in the cell cycle of all three organisms.  
1.4.3.3. Peptidoglycan architecture of S. aureus (gram-positive cocci) 
 
Studies of S. aureus peptidoglycan architecture were carried out using whole cells and sacculi (Touhami et al., 
2004; Turner et al., 2010). Two distinct peptidoglycan organisations are visible in S. aureus: knobbly material 
and concentric rings (Figure 1.4). The knobbly architecture was thought to display a honeycomb pattern after 
high resolution AFM whole cell studies (Touhami et al., 2004). Studies of purified sacculi do not display this, 
suggesting that teichoic acids and cell wall proteins may be responsible for the pattern. The newly synthesised 
septal plate displays a concentric ring architecture. After cell division, the septum, which is less voluminous 
than the hemisphere it becomes, needs to be remodelled. Through this remodelling process, the 
peptidoglycan architecture changes from concentric rings to mature peptidoglycan with a knobbly architecture 
(Turner et al., 2010). The growth of the new cell wall and the ensuing change in peptidoglycan architecture is 
thought to be due to the combined action of hydrolases and turgor pressure. There is no data suggesting any 
specific glycan chain orientation in S. aureus (Turner et al., 2014).  
The two peptidoglycan architectures are separated by a thick ring of peptidoglycan known as the piecrust 
(Turner et al., 2010). The piecrust feature is posited to play a role in the correct localisation of the next division 
plane (Figure 1.5). When S. aureus divides, the cell splits in the plane of a newly formed piecrust and each 
daughter cell will inherit half of the piecrust feature. This is then named a rib, as it is less distinct then a 
piecrust. Upon formation of the following piecrust and cell division, the full rib from the previous cycle will be 
halved and the cell will get a new rib going all around the cell from the split piecrust from the current cell 
division cycle (Turner et al., 2010). The next division cycle will give the cells a quarter rib, a half rib and a whole 
rib (Figure 1.5). The quarter-rib is thought to dictate the location of the next division plane (a new piecrust will 
be synthesised in this plane). All the ribs intersect at roughly right angles. The presence of the ribs is proposed 





Figure 1.5. Piecrust location and remodelling in S. aureus. Ribs are the remnants of piecrusts from previous 
generations. A new piecrust is formed in the plane of the quarter rib, this is the first step of septum formation. 
Upon cell division, the rib will be split in two and the daughter cells will have a new rib pattern. This pattern 
specifies the next division plane (same plane as the new quarter rib). (a, b, c) AFM height (H) and phase (P) 
images showing ribs and rib junctions. (d) Model of piecrust remodelling throughout the cell cycle. 




1.5. Cell wall synthesis 
1.5.1. PG synthesis 
 
Peptidoglycan synthesis can be split into four stages: precursor synthesis, assembly of the lipid linked 
muropeptides, flipping of lipid II across the membrane, monomer polymerisation (Typas et al., 2012)(Figure 
1.6). The peptidoglycan synthesis pathway is conserved in gram-positive and gram-negative organisms.  
1.5.1.1. Precursor synthesis 
 
Peptidoglycan precursor synthesis takes place in the cytoplasm. The first step in precursor synthesis is the 
transfer of enolpyruvyl from phosphoenolpyruvate (PEP) to uridine diphosphate (UDP)-GlcNAc. This reaction is 
catalysed by MurA and produces enolpyruvyl UDP-GlcNAc (Lovering et al., 2012). Next, enolpyruvyl UDP-
GlcNAc is converted into UDP-MurNAc. This step is catalysed by the reductase MurB and is NADPH-dependent 
(Lovering et al., 2012). The pentapeptide side chain is then assembled onto UDP-MurNAc in a stepwise 
manner. The assembly is catalysed by four highly conserved Mur ligases: MurC, MurD, MurE and MurF (Bouhss 
et al., 1997; Eveland et al., 1997). MurC catalyses the addition of ʟ-Ala to UDP-MurNAc generating UDP-
MurNAc-ʟ-Ala. ᴅ-Glu is then added onto the MurC product by MurD. MurE catalyses the addition of the third 
side chain peptide. The third peptide varies in different species, with the addition of meso-DAP in E. coli and 
addition of ʟ-Lys in S. aureus. The final two ᴅ-Ala units are added to the peptide side chain in one step as a ᴅ-
Ala-ᴅ-Ala dipeptide. This final step is catalysed by MurF (Lovering et al., 2012).  
1.5.1.2. Lipid II assembly 
 
The next step of peptidoglycan synthesis involves transfer of the UDP-MurNAc-pentapeptide onto the 
undecaprenyl phosphate carrier Und-P, which is anchored in the membrane (Lovering et al., 2012). This step is 
catalysed by MraY, a membrane protein (Bouhss et al., 2004). The membrane-associated product of this 
reaction is commonly known as lipid I. Finally, MurG catalyses the attachement of UDP-GlcNAc to lipid I giving 
lipid II. The MraY and MurG reactions are coupled to avoid unnecessary accumulation of precursors. This 
cooperation allows the cell to have a small pool of lipid I and lipid II: approximately 700 molecules/cell and 
2000 molecules/cell respectively in E. coli (van Heijenoort et al., 1992). 
1.5.1.3. Flipping of lipid II across the membrane 
 




Figure 1.6. Schematic of peptidoglycan synthesis in S. aureus. Precursor synthesis occurs in the cytoplasm. 
Precursors are then flipped across the membrane before being added to the cell wall peptidoglycan by 




it can be polymerised into peptidoglycan in the periplasm or exoplasm. The flippase is required to create a 
conduit for lipid II (hydrophilic) to cross the hydrophobic centre of the cell membrane lipid bilayer (Ruiz, 2015). 
The mechanism by which flipping occurs is also poorly understood. There was long a debate around whether 
FtsW/RodA type proteins or MurJ type proteins carry out this role. Recent research has elucidated other 
cellular roles of FtsW/RodA proteins in S. aureus, suggesting that MurJ is the likely flippase (Taguchi et al., 
2019). An overview of the different flippase candidates will be presented here.  
FtsW, a member of the shape, elongation, division and sporulation (SEDS) family of proteins, was shown to 
translocate lipid II across the membrane in E. coli membrane vesicles (Mohammadi et al., 2011). MurJ showed 
no such activity in this model. There is no evidence to date showing FtsW flippase activity in vivo and 
inactivation of FtsW and RodA in vivo does not inhibit lipid II translocation (Sham et al., 2014). FtsW has now 
also been shown to have glycosyltransferase activity in vitro (Cho et al., 2016; Taguchi et al., 2019). 
MurJ was identified as a candidate lipid II translocase in E. coli through a bioinformatics screen (Ruiz, 2008). 
MurJ is a member of the multidrug/oligo-saccharidyl-lipid/polysaccharide (MOP) exporter family of proteins. 
MurJ depletion is lethal in E. coli and leads to a decrease in peptidoglycan synthesis coupled with an increase 
in precursors, including lipid intermediates (Inoue et al., 2008). Deletion of MurJ in vivo results in lack of lipid II 
translocation to the outside of the inner-membrane in E. coli (Sham et al., 2014). 
1.5.1.4. Monomer polymerisation 
 
Once lipid II has been flipped to the outside of the cell membrane, it is polymerised into glycan strands by 
transglycosylases. There are monofunctional and bifunctional transglycosylases. Bifunctional transglycosylases 
also have transpeptidase activity and are known as Class A PBPs (Typas et al., 2012). PBP2 is the only 
bifunctional PBP in S. aureus, which also possesses several monofunctional transglycosylases: Mgt, SgtA and 
FtsW (Reed et al., 2011; Taguchi et al., 2019). In bacteria with the Rod system, RodA also functions as a 
transglycosylase (Emami et al., 2017). Lipid II polymerisation takes place through the formation of a glycosidic 
bond between MurNAc on the growing peptidoglycan strand and the GlcNAc residue of lipid II (Fuchs 
Cleveland & Gilvarg, 1976; Ward & Perkins, 1973). At this stage, the Und-P carrier is recycled back into the 
cytoplasm for dephosphorylation and use in peptidoglycan precursor synthesis (van Dam et al., 2009). 
The next step of peptidoglycan synthesis is crosslinking of the newly formed peptidoglycan strands (Lovering et 
al., 2012). Peptide side chains are linked via transpeptidase activity. Class B PBPs are monofunctional 
transpeptidases that carry out this activity along with the bifunctional Class A PBPs. The transpeptidase 
noncovalently binds the donor strand before forming an acyl-enzyme intermediate, releasing the terminal ᴅ-
Ala in the process (Lovering et al., 2012). The acyl-enzyme intermediate is then crosslinked with the acceptor 
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strand (another peptide side chain). Alternatively, the acyl-enzyme intermediate can be hydrolysed by water, 
releasing a shortened peptide (carboxypeptidation) (Lovering et al., 2012). 
1.5.2. WTA synthesis 
 
Genes involved in WTA biosynthesis in S. aureus are called tar (teichoic acid ribotol) genes. WTA synthesis 
begins with TarO, which transfers GlcNAc onto a membrane linked Und-P carrier lipid (Brown et al., 2008). 
TarA then transfers ManNAc onto the C4 hydroxyl of GlcNAC forming ManNac-β-(1,4)-GlcNAC-pp-udp. Next, 
glycerol-3-phosphate is added to the C4 hydroxyl of the ManNAc residue by TarB. TarF adds one GroP to the 
disaccharide unit. Finally, TarL is responsible for building the polyribitol-phosphate polymer through addition 
of CDP-ribitol monomers (Brown et al., 2008). Deletion of tarO in S. aureus is not lethal allowing for the study 
of a population lacking the wall teichoic acid biosynthetic pathway and therefore lacking WTAs.  
1.5.3. LTA synthesis 
 
The first step of LTA biosynthesis involves production of the glycolipid anchor in the cytoplasm by YpfP, a 
glycosyltransferase (Percy & Gründling, 2014)(Figure 1.7). The glycolipid anchor is then flipped across the cell 
membrane, possibly by LtaA. LtaS then synthesises the GroP chain using GroP subunits which are derived from 
the head group of lipid phosphatidylglycerol found in the membrane. The number of LtaS-type enzymes 
involved in GroP chain synthesis varies from species to species (Percy & Gründling, 2014). LTA synthesis is 
closely linked to lipid biosynthesis and turnover due to its use of lipid phosphatidylglycerol from the 
membrane. In fact, the cellular pool of lipid phosphatidylglycerol  is thought to be turned around more than 
twice per generation to allow for sufficient LTA synthesis (Koch et al., 1984). 
1.6. Peptidoglycan hydrolysis 
 
Peptidoglycan hydrolases play a role in a large number of cellular processes from cell growth, cell division and 
autolysis to peptidoglycan turnover and sporulation (Vollmer et al., 2008). There is a hydrolase capable of 
hydrolysing every bond found in peptidoglycan (Figure 1.8): 
• Acetylmuramyl-ʟ-alanine amidases (amidases) hydrolyse the amide bond between MurNAc and ʟ-
alanine separating the sugar backbone and the peptide side chain. 
• Carboxy- and endopeptidase (peptidases) cleave the different bonds between ᴅᴅ- and ʟᴅ-amino acids 
in the peptide side chains. 
• N-acetylglucosaminidases (glucosaminidases) cleave the bond in the sugar back bone between the 










Figure 1.8. Peptidoglycan hydrolase activity. (A) Cleavage sites on the peptide side chain. (B) Cleavage side on 
the glycan backbone. 1 – Glucosaminidases; 2 – lysozyme-like; 3 – lytic transglycosylases. Adapted from 
(Vollmer et al., 2008).  
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• N-acetyl-β-ᴅ-muramidases (muramidases) hydrolyse the β1,4-glycosidic bond between MurNAc and 
GlcNAc residues. Lysozyme-like enzymes and lytic transglycosylases are the two types of muramidases. 
Peptidoglycan hydrolases play important roles throughout the cell cycle, which is reflected in the high amount 
of redundancy amongst them. Bacteria often have several different enzymes that can cleave each bond, and 
even the different classes of enzymes have overlapping functions. E. coli has at least 13 peptidoglycan 
hydrolases located in its periplasm (Typas et al., 2012). PscB in Streptococcus pneumoniae is the only hydrolase 
known to be individually essential (Ng et al., 2004). There are however, examples of essential groups of 
hydrolases. In S. aureus, the four putative glucosaminidases, SagA, SagB, ScaH and Atl are essential as a group 
(Wheeler et al., 2015). In B. subtilis YvcE and LytE cannot both be absent, and in E. coli, lack of Spr, YdhO and 
YebA is synthetically lethal (Bisicchia et al., 2007; Singh et al., 2012). 
1.6.1. S. aureus hydrolases 
 
There is a total of 19 known putative hydrolases in S. aureus. All of these have been listed in Table 1.1. Many 
of the hydrolases are not characterised. Most of the uncharacterised hydrolases have been identified as having 
a cysteine, histidine-dependent amidohydrolases/peptidases (CHAP) domain. Enzymes with a CHAP domain 
are proposed to act as peptidoglycan hydrolases (Bateman & Rawlings, 2003). In S. aureus, all the Sca proteins 
have CHAP domains (Pourmand et al., 2006).  
Atl is one of the best characterised peptidoglycan hydrolases in S. aureus. atl encodes a 137 kDa protein, which 
is exported and processed into two hydrolases, one glucosaminidase (C-terminal domain) and one amidase (N-
terminal domain) (Foster, 1995). Atl has been linked to the secretion of proteins, cell division, post-death lysis 
and peptidoglycan release from the cell surface (Foster, 1995; Pasztor et al., 2010; Wheeler et al., 2015). In a 
wild-type cell, Concanavalin A (ConA, a lectin that binds WTA) labelling revealed that WTA are not found at the 
septum. WTA localisation dictates Atl localisation, excluding Atl due to changes in proton-binding sites 
available in the cell wall (Biswas et al., 2012). Thus Atl is located at the centre of the septal plate through the 
absence of WTA in the septal plate peptidoglycan (Schlag et al., 2010). In a strain lacking WTA, Atl is observed 
all across the cell wall (Schlag et al., 2010). Lack of WTA therefore leads to faster lysis using Triton X-100 
autolysis assays because Atl can act across the entire cell wall.   
Atl is one of four putative glucosaminidases with ScaH, SagB and SagA (Wheeler et al., 2015). As a group 
glucosaminidases are essential and are involved in reshaping new cell wall after cell division. Their action 
allows for cell expansion and a decrease in cell wall stiffness through glycan chain shortening (Wheeler et al., 
2015). SagB was shown to play the biggest role in shortening of glycan strands (Wheeler et al., 2015). 
IsaA and SceD are the two putative lytic transglycosylases identified in S. aureus. When IsaA is absent, ScaD 
(CHAP domain containing) and SceD are both present in greater quantities, likely as a compensation  
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Protein Putative identification References 
Atl Amidase & Glucosaminidase (Foster, 1995; Oshida, Takano, Sugai, 
Suginaka, & Matsushita, 1998; Wheeler et al., 
2015) 
SagA Glucosaminidase (Wheeler et al., 2015) 
SagB Glucosaminidase (Wheeler et al., 2015) 
ScaA/Sle1/Aaa Amidase & CHAP domain (Heilmann et al., 2005; Pourmand et al., 
2006) 
ScaB CHAP domain (Pourmand et al., 2006) 
ScaC CHAP domain (Pourmand et al., 2006) 
ScaD CHAP domain (Pourmand et al., 2006) 
ScaE CHAP domain, LysM domain (Pourmand et al., 2006) 
ScaF CHAP domain (Pourmand et al., 2006) 
ScaG CHAP domain (Pourmand et al., 2006) 
ScaH Glucosaminidase & CHAP 
domain 
(Pourmand et al., 2006; Wheeler et al., 2015) 
ScaJ CHAP domain (Pourmand et al., 2006) 
IsaA Lytic transglycosylase (M. R. Stapleton et al., 2007) 
LytM Lysostaphin (Ramadurai & Jayaswal, 1997) 
LytN Amidase/Endopeptidase (Frankel et al., 2011; Sugai et al., 1998) 
SceD Lytic transglycosylase (M. R. Stapleton et al., 2007) 
SA0191 Lysostaphin (Wheeler, 2012) 
LytH Amidase (Wheeler, 2012) 
SA2195 Lysostaphin (Wheeler, 2012) 




mechanism (Stapleton et al., 2007). The upregulation of sceD after isaA inactivation suggests the two 
hydrolases have overlapping functions. SceD is thought to be involved in peptidoglycan remodelling in high salt 
environments (Stapleton et al., 2007; Vijaranakul et al., 1995). In the presence of high levels of NaCl, sceD 
expression levels go up. Lack of IsaA and SceD also leads to an increased degree of clumping, suggesting the 
hydrolases play a role in cell division (Stapleton et al., 2007). IsaA and SceD are also required for virulence 
(Stapleton et al., 2007). 
Mutants lacking Sle1 or LytN showed impaired cell division, with excessive cell clumping, suggesting both 
hydrolases play a role in cell division (Frankel et al., 2011; Kajimura et al., 2005). LytN and Sle1 both contain a 
LysM domain. The LysM and CHAP domains are required for binding of LytN to peptidoglycan (Frankel & 
Schneewind, 2012). The LysM domain is required for LytN and Sle1 association with peptidoglycan void of 
WTA, and as a consequence, localisation to the septum (Frankel & Schneewind, 2012). The LysM domain is not 
essential for LytN but is for Sle1 function. 
1.6.2. Control of S. aureus hydrolases 
 
Due to the large number of hydrolases in S. aureus, and the fact that only a subset of them have been studied, 
there is only limited understanding of how hydrolase activity is controlled. Tight restrictions on hydrolase 
activity are however important to ensure a perfect balance between peptidoglycan synthesis and hydrolysis 
throughout the cell cycle. Hydrolases are controlled by a complex web of cellular regulators. IsaA and SceD 
provide good examples of the complexity of hydrolase regulation in S. aureus. IsaA is positively regulated by 
SarA, YycFG (WalKR) and oxygen levels (Fuchs et al., 2007; Stapleton et al., 2007). SarA, LytSR and SaeR are 
negative regulators of SceD and sigma factor B (σB) , Agr, and YycFG/WalKR are positive regulators (Stapleton 
et al., 2007).  
The WalKR/YycFG two-component system (TCS) plays a major role in regulation of the cell wall metabolism 
and is essential in S. aureus (Dubrac et al., 2007; Dubrac & Msadek, 2004). WalK is a histidine kinase and WalR 
is a response regulator. A conditional (IPTG-dependant WalKR expression) mutant has been used to study the 
effect of WalKR depletion on cells. The following putative hydrolases are thought to be positively controlled by 
WalKR: Atl, ScaB, ScaC, ScaD (SsaA), ScaE, ScaJ, IsaA, LytM, SceD (Dubrac et al., 2007). These hydrolases have 
different activities, amongst them are glucosminidases, transglycosylases/muramidases, amidases and 
endopeptidases. WalKR-depleted cells aggregate more and are more lysis resistant than wild-type cells 
(Dubrac et al., 2007). Due to the diminished hydrolase activity in a WalKR mutant, cells develop thick cell walls 
and do not divide correctly (Delaune et al., 2011). The absence of WalKR can be partially complemented by 
LytM and ScaD/SsaA. This suggests that depletion of WalKR leads to cell death through an imbalance between 
cell wall synthesis and cell wall hydrolysis.  
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1.7. Cell division – overview 
 
Cell division refers to the fundamental process of bacterial replication. Prokaryotes predominantly replicate by 
binary fission. Cells replicate and segregate their chromosomes, ensuring each daughter cell gets an identical 
set before forming a septum, normally placed at the mid-cell, and dividing. The correct execution of these 
steps is extremely important and spatial and temporal control are crucial.  
1.7.1. Rod-shaped bacteria 
 
Before cell division can take place, rod-shaped bacterial cells elongate. The increase in cell length allows cells 
to increase in volume while maintaining a constant diameter. Cell division will only occur once cells have 
reached a minimum length (Donachie & Begg, 1989; Sharpe & Errington, 1998). Chromosome segregation then 
takes place and septum formation can begin without risking uneven chromosome distribution in the daughter 
cells. Once complete, the septum is hydrolysed and the cell splits into two daughter cells. Correct selection of 
the division plane is extremely important.  
Temporally, cells must divide only when they have reached the correct size, which is in large part determined 
by nutrient availability. In B. subtilis, nutrient availability leads to faster growing, longer cells and growth in 
nutrient poor media leads to shorter cells (Sargent, 1975). The glucosyltransferase UgtP localises at the 
septum in a nutrient-dependant manner and inhibits FtsZ assembly (Weart et al., 2007). A 1:1 FtsZ:UgtP ratio 
results in 90% inhibition of FtsZ assembly. In nutrient rich environments, UgtP is highly expressed and localised 
across the cytoplasm with a high concentration at the midcell in exponential phase (Weart et al., 2007). In the 
nutrient rich media, UgtP allows for increased elongation. 
Spatially, the septum is precisely positioned at the mid-cell with little deviation (~1%) (Trueba, 1982). Septum 
formation begins with the localisation of FtsZ to the mid-cell and assembly of the Z-ring. The Z-ring recruits 
other cell division components. In E. coli and B. subtilis, the Min system and nucleoid occlusion are responsible 
for Z-ring positioning. In E. coli, MinC, MinD and MinE form the Min system (Raskin & De Boer, 1997). MinC 
and MinD form a complex (MinCD) which negatively regulates the Z-ring due to MinC inhibiting FtsZ 
polymerisation through direct interaction with it. MinE prevents MinC activity at the mid-cell allowing correct 
localisation of the Z-ring. MinC and MinD have been shown to oscillate from one pole to the other as a result 
of which MinC concentrations are highest at the poles, inhibiting FtsZ assembly (Hu & Lutkenhaus, 1999). B. 
subtilis has MinCD homologues but not MinE. Instead, DivIVA acts as a topological factor. DivIVA recognises 
cell curvature and localises at the poles (Bramkamp et al., 2008; Lenarcic et al., 2009). With the aid of MinJ, 
DivIVA recruits MinD to the cell poles then recruits MinC, thus inhibiting z-ring assembly at the poles. The 
relocation of MinC from the old poles to the site of division suggests that it may also inhibit the assembly of 
more than one Z-ring at the mid-cell (Migocki et al., 2002). Nucleoid occlusion keeps the cell from dividing near 
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the chromosome and bisecting the nucleoid. Nucleoid occlusion is achieved through binding of Noc in B. 
subtilis and SlmA in E. coli to specific DNA sequences (Wu & Errington, 2012). Noc inhibits FtsZ assembly 
through its physical presence. SlmA prevents the organisations of FtsZ protofilaments into a higher 
organisation (Bernhardt & De Boer, 2005).  
1.7.2. Coccoid bacteria 
 
In coccoid bacteria there are theoretically an infinite number of potential division planes (Figure 1.9). 
Consequently, division plane selection is more complex. Some coccoid bacteria divide in a single plane (like 
rod-shaped bacteria), other divide in two or three planes (Zapun et al., 2008). For example, S. aureus divides 
successively in three orthogonal planes (Tzagoloff & Novick, 1977). In this case, the organism requires a way of 
knowing the division plane from the two previous divisions. This process is unlikely to be encoded in the DNA 
due to it changing every division cycle. It has been hypothesised that rib/piecrust features in the 
peptidoglycan, that are remnants from previous division cycles, play a role in the correct choosing of the next 
division plane in S. aureus (Turner et al., 2010). WTA localisation may also play a role in in mid-cell localisation 
(Atilano et al., 2010; Schlag et al., 2010).  
S. aureus has not been found to have a Min homologue, it does however have a Noc homologue (Veiga et al., 
2011). This process is particularly important in S. aureus because its nucleoid occupies a large part of the 





Figure 1.9. Schematic of different bacterial division planes. Division in (a) two perpendicular planes, (b) three 




1.8. Cell division – the divisome 
 
A large network of proteins is required to carry out cell division (Figure 1.10). FtsZ is the most highly conserved 
of these and is thought to initiate the process of cell division in E. coli (Margolin, 2000). FtsZ localises at the site 
of new septum formation and polymerises into protofilaments (D. J. Scheffers & Driessen, 2001). These 
protofilaments organise into a dynamic structure with a short protein turnover time, known as the Z-ring. FtsZ 
can cause constrictions in liposomes suggesting that it drives the cell constriction required for cell division. FtsZ 
filament sliding in a complete circle has been hypothesised to be responsible for generating constriction force 
(Szwedziak et al., 2014). In gram-positive bacteria FtsZ appears to have a dynamic bead-like structure (Strauss 
et al., 2012).  
FtsZ requires other proteins to carry out its role in cell division. FtsA, a membrane-associated protein, enables 
FtsZ polymers to assemble at the membrane. Formation of the FtsA-FtsZ complex allows for strong enough 
anchoring to the cell membrane (Loose & Mitchison, 2014). In E. coli a second protein, ZipA, appears to carry 
out a similar function. Both FtsA and ZipA are required for FtsZ lead constriction even though the Z-ring can 
still form in the presence of only one of them (Pichoff & Lutkenhaus, 2002). ZipA and FtsA together are also 
credited with recruiting FtsK and other division proteins (Pichoff & Lutkenhaus, 2002). A large number of other 
FtsZ-interacting proteins help maintain the Z-ring. In E. coli these include ZapA, ZapC and ZapD (Durand-
Heredia et al., 2011; Galli & Gerdes, 2010). In B. subtilis and S. aureus, SepF is involved (Hamoen et al., 2006). 
EzrA plays an important role in gram-positive cell division, playing an essential role in S. aureus although not in 
B. subtilis (Levin et al., 1999; Steele et al., 2011). EzrA is essential for correct cell growth, localisation of cell 
division proteins and peptidoglycan synthesis (Steele et al., 2011). There are two proposed models of EzrA-FtsZ 
interaction. The first proposes that EzrA, which is arch shaped, traps FtsZ filament anchoring the 
protofilaments to the membrane and inhibiting any lateral interactions (Cleverley et al., 2014). It would also be 
possible for FtsZ to interact with the outer surface of the EzrA ring, allowing another molecule to bind the 
inside of the arch (Cleverley et al., 2014). Once the Z-ring is fully assembled other cell division components are 
recruited to the mid-cell. In E. coli these include FtsK, FtsQ, FtsL, FtsW, FtsI, FtsN, FtsQ, FtsB and FtsL (Pichoff & 
Lutkenhaus, 2002). In S. aureus the late stage division proteins include FtsL, DivIC, DivIB, FtsW and GpsB 
(Daniel & Errington, 2003; Steele et al., 2011). PBPs are also recruited for peptidoglycan synthesis and 





Figure 1.10. Diagram of the cell division machinery in (A) E. coli (B) B. subtilis. Analogues in E.coli and B. 
subtilis have been represented in the same colours. This diagram is not exhaustive, some interactions are not 




1.8.1. Penicillin-binding proteins 
 
Penicillin-binding proteins play an integral role in peptidoglycan biosynthesis. PBPs are enzymes with 
transglycosylation and/or transpeptidation activity (Sauvage et al., 2008). PBPs are of particular interest 
because they are the targets of the β-lactam class of antibiotics, giving them their name. Modifications to PBPs 
play a major role in antibiotic resistance (Zapun et al., 2008).  
PBPs are split into two classes: high molecular weight (HMW) and low molecular weight (LMW).  HMW PBPs 
are further split into class A and class B. Class A PBPs are bifunctional, they have both transpeptidase and 
transglycosylase activity (Sauvage et al., 2008). Class B PBPs only have transpeptidase activity. Both classes 
have C-terminal domains with transpeptidase activity linked by a β-sheet rich linker to N-terminal domains of 
differing functions (Lovering et al., 2012; Sauvage et al., 2008). The N-terminal domains of A PBPs has 
transglycosylase activity and that of B PBPs is of unknown function. LMW PBPs possess endopeptidase activity 
(crosslinking) or carboxypeptidase activity, which prevents further crosslinking through hydrolysis of the 
peptide side chain (Macheboeuf et al., 2006).  
There is a great amount of variation in the number of PBPs present in different bacteria. This partially reflects 
differences in growth and division modes. E. coli has 12 PBPs, B. subtilis has 16 PBPs and S. aureus only has 4 
PBPs (Sauvage et al., 2008). PBP1, PBP2, PBP3 and PBP4 are the four PBPs identified in S. aureus. PBP1 and 
PBP3 are class B HMW PBPs, PBP2 is a class A PBP and PBP4 is a LMW PBP. PBP1 and PBP2 localise at the 
septum and are both essential although PBP1 essentiality is thought to be independent of its transpeptidase 
activity (Pereira et al., 2009). Recently, it has been revealed that PBP1 is essential for FtsW transglycosylase 
activity (Reichmann et al., 2019; Taguchi et al., 2019). PBP1 and FtsW form a SEDS-bPBP pair, which may 
explain PBP1 essentiality. PBP4, the sole LMW PBP, has transpeptidase activity and is attributed with the high 
levels of crosslinking present in S. aureus peptidoglycan (Wyke et al., 1981). Deletion of PBP4 leads to a 
reduction in PBP2 transcription and in peptidoglycan crosslinking (Memmi et al., 2008). Lack of PBP3 does not 
lead to significant changes in muropeptide composition of the cell wall. It does however cause a small 
decrease in autolysis, suggesting it plays a role in cell division (Pinho et al., 2000).  Recent data revealed that 
PBP3 is required for the correct localisation of RodA (a SEDS protein) at the midcell and that they form a SEDS-
bPBP pair (Reichmann et al., 2019). In MRSA, an additional PBP is present, PBP2A, encoded by mecA (Hartman 
& Tomasz, 1984). PBP2A has a lower affinity to β-lactams than PBP2, allowing for continued transpeptidase 
activity in S. aureus after antibiotic treatment (Lim & Strynadka, 2002). The transglycosylase activity of PBP2 is 
still required to achieve high levels of resistance. 
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1.9. Cell division – peptidoglycan dynamics 
1.9.1. Peptidoglycan synthesis 
 
The location of peptidoglycan synthesis varies in different organisms. Where peptidoglycan is inserted into the 
sacculus has an impact on cell shape and growth. Fluorescent vancomycin and fluorescent ᴅ-amino acids are 
effective probes used to look at patterns of peptidoglycan insertion across the cell (Daniel & Errington, 2003). 
In both E. coli and B. subtilis a focus of insertion is found at the septum. In E. coli, STORM imaging of 
vancomycin-labelled cells and sacculi revealed that peptidoglycan insertion, for cell elongation, occurs in many 
discrete foci spread over the cylinder of the cell (Turner et al., 2013). These results disagree with earlier 
imaging showing a helical pattern of insertion (Varma et al., 2007). The difference can be explained by the use 
of higher resolution imaging in the more recent study, allowing for more precise localisation. In B. subtilis 
vancomycin labelling revealed a helical pattern of peptidoglycan incorporation (Varma et al., 2007). The Mre 
proteins have been proposed to be responsible for cell shape in B. subtilis (Daniel & Errington, 2003). There 
are three MreB homologs in B. subtilis: MreB, MbI and MreBH. The three homologs were thought to form a 
dynamic cable but they have recently been shown to move independently (Domínguez-Escobar et al., 2011). 
MreC and MreD stabilise the MreB cytoskeleton and MreB is thought to recruit peptidoglycan biosynthesis 
proteins as well as contribute to their coupling with peptidoglycan precursors (Leaver & Errington, 2005).  
In S. aureus, peptidoglycan synthesis occurs in a dispersed manner across the whole of the cell wall and the 
septum, with no discreet foci (Lund et al., 2018). Localisation of peptidoglycan synthesis in S. aureus is 
determined by FtsZ, due to its central role in the localisation of the peptidoglycan biosynthesis machinery. At 
the septum, peptidoglycan is inserted in a region of insertion around the leading edge of the septum (Lund et 
al., 2018)(Figure 1.11). The leading edge is thinner than the lagging edge. Once the septum forms a connected 
septal plate, the centre is still thinner, and further incorporation forms a septum of uniform width before cell 
division occurs (Lund et al., 2018).  
1.9.2. Cell splitting 
 
After completion of the septum, cells need to split into two daughter cells. Peptidoglycan hydrolases are 
thought to be responsible for the splitting of the septal plate into two halves (Giesbrecht et al., 1997). In gram-
negative bacteria the mid-cell is also constricted and the outer-membrane needs to be separated. To carry out 
cell division hydrolases are localised to the cell septum, although no direct interaction has been shown 





Figure 1.11. Model of peptidoglycan insertion in S. aureus. (i, ii) Cell size increase before septum formation 
begins. (iii, iv) Septum formation begins at the piecrust. The septum is thinnest at the leading edge. (v) Annulus 
fuses. (vi) Synthesis continues to complete a septal plate of homogenous width. (vii, viii) cell division. 




In E. coli the three amidases, AmiA, AmiB and AmiC, play a major role in hydrolysis of the septal plate (Höltje & 
Heidrich, 2001). Cell splitting can take place with only one of the amidases but at a slower rate. It has been 
shown that lytic transglycosylases (Slt70, MltA, MltB) and endopeptidases (MepA, PBP4, PBP7) are also 
involved in the process but play a much smaller role (Höltje & Heidrich, 2001). In B. subilis, LytF and CwlF are 
thought to be involved in hydrolysis of the septum during cell division (Ohnishi et al., 1999).  
In S. aureus Atl, Sle1, IsaA and SceD are the major autolysins involved (Biswas et al., 2012; Kajimura et al., 
2005; Stapleton et al., 2007; Wheeler et al., 2015). Atl is thought to play the biggest role in hydrolysis of the 
septum into its two component parts. Atl is a bifunctional enzyme, which is proteolytically cleaved into an 
amidase and a glucosaminidase (Biswas et al., 2006). It is located at the septum with foci around the pie crust 
feature (Yamada et al., 1996). Its localisation is thought to be due to the lack of WTA at the septum. Mutants 
lacking Atl or Sle1 form clusters, suggesting a lack of complete cell division. Deletion of IsaA and SceD, lytic 
transglycosylases, also leads to impaired cell division. Live-microscopy has revealed that daughter cell 
separation occurs on a millisecond timescale (Zhou et al., 2015). This rapid separation is thought to be driven 
by mechanical forces. Cell separation is therefore initiated by hydrolase activity and ends in mechanical 
separation (Zhou et al., 2015).  
1.9.3. Cell expansion 
 
After splitting, the daughter cell must grow before it can itself divide. Hydrolases have been proposed as one 
of the main drivers of sacculus enlargement. A careful balance between hydrolysis and synthesis is required to 
maintain cell wall integrity during growth. The three-for-one model of peptidoglycan insertion was developed 
as a possible way cells maintain this balance (Figure 1.12). A peptidoglycan triplet is crosslinked to the inner of 
the cell wall through free amino groups on the crossbridges between backbone sugars (Höltje & Heidrich, 
2001). As a result, the triplet is bound to the peptidoglycan either side of the loading strands. This allows the 
triplet to remain unstressed, while the rest of the wall is load bearing (Höltje & Heidrich, 2001). The loading 
strand is hydrolysed out of the peptidoglycan consequently incorporating the triplet into the stress bearing 
peptidoglycan chain. This model can be used for both gram-negative and gram-positive cell walls (Höltje & 
Heidrich, 2001).  
In S. aureus, after cell division the septum must be remodelled to form mature peptidoglycan. The reshaping 
of the new cell wall is the growth mechanism used by S. aureus before the next round of septum formation 
begins (Bailey et al., 2014; Wheeler et al., 2015). After daughter cell splitting, the newly exposed material is 
stiffer than the rest of the cell wall (Bailey et al., 2014). The newly exposed peptidoglycan’s stiffness decreases 
as the wall expands to gain a spherical shape. The four putative glucosaminidases, Atl, SagA, SagB and ScaH 
have been shown to be responsible for this remodelling process (Wheeler et al., 2015). The cell wall of a 




Figure 1.12. Representation of the proposed three-for-one peptidoglycan growth model. Circles represent 
glycan strands crosslinked by peptide side chains represented in bar form. (A) Hypothetical mechanism in a 
thin, gram-negative-like cell wall. (B) Hypothetical mechanism in a thick, gram-positive-like cell wall. Modified 




stiffer. SagB plays the biggest role in this process out of the four enzymes (Wheeler et al., 2015). The 
glucosaminidases’ remodelling of the new peptidoglycan is responsible for the short glycan chain length in S. 
aureus (Boneca et al., 2000).  
1.10. Cell Wall antibiotics 
 
The cell wall and its associated machinery are highly conserved across bacterial species and are not present in 
mammalian cells, making them excellent targets for antibiotics. Additionally, many of them are essential (Bugg 
et al., 2011; Lovering et al., 2012). Most cell wall antibiotics are natural products isolated from other organisms 
that produce them for competition in their native environments (Bugg et al., 2011). The steps targeted by cell 
wall antibiotics can be split into three categories: cytoplasmic steps, lipid-linked steps and cell 
surface/assembly steps. Most currently used cell wall antibiotics target the lipid-linked and assembly steps of 
peptidoglycan synthesis (Figure 1.13). Only ᴅ-cycloserine and fosfomycin target peptidoglycan precursor 
synthesis.  
Antibiotic resistance is a rising global issue. A recent study estimated that antibiotic resistant infections caused 
33110 deaths in the European Economic Area (EEA) in 2015 (Cassini et al., 2019). The burden (deaths and 
disability-adjusted life years) increased for all antibiotic-resistant infections between 2007 and 2015 (Cassini et 
al., 2019). As a consequence, new antibiotic development is required and the cell wall is an excellent target to 
consider in this context.  
The two most widely used classes of cell wall antibiotics are β-lactams and glycopeptides. We have a good 
understanding of their targets but only limited understanding of how binding to these targets leads to cell 
death. A better understanding of the cellular pathway to cell death could provide insight into potential new 
targets for antimicrobials and offer a better understanding of resistance mechanisms. Our current 
understanding of β-lactams and glycopeptides is presented below.  
1.11. β-lactams 
 
β-lactams are cell-wall synthesis inhibiting antibiotics. β-lactams are chemically defined by their β-lactam ring, 
a four membered lactam (Aoki & Okuhara, 1980). β-lactams are commonly subdivided according to their 
chemical structure into penams, cephems, monobactams and carbapenems. β-lactams are PBP substrate 
analogues and act as inhibitors of PBP function (Tipper & Strominger, 1965). β-lactams mimic the D-ala-D-ala 
dipeptide, that is found at the end of the peptide side chain of peptidoglycan. They inhibit PBP function by 
acylating the active site serine hydroxyl group. The deacylation is very slow, forming a covalent acyl-enzyme 









β-lactams are bactericidal antibiotics that only act on cells that are actively growing and dividing, not on 
stationary phase cells. It has long been accepted that β-lactam killing occurs through an imbalance between 
peptidoglycan synthesis and hydrolysis (A Tomasz, 1979). However, this has been more of an accepted idea 
rather than a proven model. Peter Giesbrecht created the most comprehensive model of β-lactam killing, 
specifically penicillin killing, of S. aureus (Giesbrecht et al., 1998). More recent research has focused on β-
lactam resistance, rather than mechanism of action, in S. aureus, or used other model organisms, often E. coli, 
to study the killing mechanism of β-lactams (Banzhaf et al., 2012; Cho, Uehara et al., 2014; Chung et al., 2009). 
1.11.1. Original models of penicillin killing 
 
Early in the study of the action of β-lactams, researchers came to the conclusion that β-lactams inhibit 
peptidoglycan crosslinking (Tipper & Strominger, 1965; Wise & Park, 1965). It was postulated that long 
uncrosslinked glycan chains were being incorporated into the cell wall. The uncrosslinked material forms a 
weaker cell wall. Continued production of cytoplasmic material was suggested to lead to swelling of the 
cytoplasm, eventually bursting the weakened cell wall (Tipper & Strominger, 1965; Tomasz, 1979). Later 
evidence showed that post-treatment lysis did not take place in autolysin deficient pneumococci and B. subtilis 
(Tomasz et al., 1970). This suggests that the observed lysis is enzymatically driven, not mechanically. β-lactams 
appeared to act in a more bacteriostatic than bactericidal manner in the autolysin-deficient strains. These 
results ushered in the idea that inhibition of PBPs was the cause for cell growth arrest but that killing was due 
to other cellular processes, one of which may be peptidoglycan hydrolysis (Tomasz, 1979). Other results from 
the same lab showed that penicillin-induced generalised cell lysis did not occur and penicillin tolerance was 
observed when experiments were done at a low pH 5 instead of pH7/7.5 (Goodell et al., 1976). It was 
hypothesised that the low pH either inhibited hydrolase activity and/or stabilised the plasma membrane 
(Goodell et al., 1976). 
1.11.2. Peter Giesbrecht’s model of penicillin killing of S. aureus 
 
When treated with 0.1 µg/mL penicillin, S. aureus dies when initiating the second cell cycle after addition of 
the antibiotic (Giesbrecht et al., 1998)(Figure 1.14). During the first cell cycle after addition of penicillin, the 
bacteria can no longer crosslink their newly incorporated glycan chains, but they continue synthesising at the 
septum. This leads to lose, mesh-like material forming large, deformed septa and the cells do not divide. In the 
next cell cycle, instead of forming a new septum, S. aureus continues to add material to the existing, 
malformed septum (Giesbrecht et al., 1998). However, instead of initiating cell splitting at the location of the 
existing septum, the murosomes perforate the cell wall at the location where the cell should have laid a new 
septum but didn’t (Giesbrecht et al., 1998). The perforation of the cell wall at 90° from the septum leads to 




Figure 1.14. Giesbrecht’s model of penicillin induced death. After penicillin treatment cells finish their current 
division cycle before dying upon initiation of the second cell division and lysing within 80 minutes of 
treatment. Reproduced from (Peter Giesbrecht et al., 1998).  
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addition (Giesbrecht et al., 1998). Generalised lysis is thought to be due to the action of remaining hydrolases 
after death of the cell. 
At higher concentrations of penicillin, 10 µg/mL, a second type of cell death is observed (Giesbrecht et al., 
1994). A subset of the population dies within 15 to 20 minutes of penicillin being added to the growth media. 
Cells that had incomplete septa upon addition of the antibiotic attempt to divide along their incomplete septa 
and puncture a hole in their cell wall, leading to loss of cytoplasm (Giesbrecht et al., 1994). At higher 
concentrations, this subset is therefore dying from attempting to split along an incomplete septum rather than 
a non-existent septum. 
1.11.3. Reactive oxygen species (ROS) 
 
The production of reactive oxygen species was proposed as a common killing mechanism for the three main 
bactericidal antibiotic classes: aminoglycosides, quinolones and β-lactams (Kohanski et al., 2007)(Figure 1.15). 
This killing model was proposed to apply to both gram-positive and gram-negative organisms and be due to 
oxidative DNA lesions. Hydroxyphenyl fluorescein (HPF) was used to measure hydroxyl radical formation after 
antibiotic treatment. Within 3 hours of treatment with quinolone, aminoglycoside and ampicillin significant 
increases in hydroxyl radical formation were observed (Kohanski et al., 2007). Decrease in lethality in the 
presence of an iron chelator or a hydroxyl radical scavenger support this model (Wang & Zhao, 2009).  
This model of killing was contradicted by subsequent studies. E. coli was still killed by β-lactams in the absence 
of oxygen and an increase in hydrogen peroxide production was not observed after treatment (Liu & Imlay, 
2013). ROS quenchers were shown to protect cells from antibiotic treatment not only in aerobic conditions but 
also in anaerobic conditions (Keren et al., 2013). These results suggest that ROS is not responsible for the 




Figure 1.15. Model of antibiotic-induced ROS killing. Drug-target interactions are proposed to trigger NADH 
oxidation through the electron transport chain and TCA cycle. This would lead to hyperactivation of the 
electron transport chain, which would in turn stimulate superoxide formation. Iron-sulfur clusters would be 
damaged by superoxide and ferrous iron would be made available triggering the Fenton reactions. This 
cascade of events would finally lead to hydroxyl radical formation and DNA damage. Reproduced from 
(Kohanski et al., 2007). 
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1.11.4. Thomas Bernhardt’s model of mecillinam killing of E. coli 
 
More recently the Thomas Bernhardt group has shown the presence of a futile cycle after β-lactam treatment 
in E. coli (Cho et al., 2014). E. coli cells were treated with mecillinam, which inhibits the TP activity of PBP2. 
PBP2 is essential to the Rod system, which is responsible for cell elongation in rod-shaped bacteria. PBP2 can 
be rendered non-essential by overproduction of FtsZ, allowing the study of the impact of treatment on cell 
wall metabolism in a strain with FtsZ upregulated. After treatment, a futile cycle of peptidoglycan synthesis 
and breakdown begins, where newly synthesised material is broken down and peptidoglycan precursor pools 
are depleted (Cho et al., 2014). Cho et al. argue that this futile cycle eventually leads to cell death by depleted 
cellular resources.  
S. aureus only has one peptidoglycan synthesis machinery, therefore conclusions based on the Rod system in a 
rod-shaped bacterium, cannot be applied to S. aureus. The effect might also differ in gram-positive vs. gram-
negative organisms. Mecillinam is also mainly used to treat gram-negative infections and is not effective 
against most gram-positive infections. This leaves us with very little understanding of the killing mechanisms in 
action when S. aureus is treated with β-lactams. 
1.11.5. Other insight into β-lactam mode of action 
 
The Kenneth Bayles group found that the homologous cidAB and lrgAB operons play a role in penicillin 
sensitivity (Groicher et al., 2000; Rice et al., 2003). LrgA acts as an antiholin inhibiting the holin-like cidA gene 
product. The presence of the cidA gene product leads to more extracellular hydrolase activity, which increases 
penicillin sensitivity (Groicher et al., 2000; Rice et al., 2003). Mutation of cidA leads to a decrease in sensitivity 
to penicillin. The difference in extracellular hydrolase activity is thought to be due to changes in hydrolase 
secretion (Rice et al., 2003).  
1.12. Glycopeptides 
 
In 1956 Eli Lilly discovered vancomycin, the first identified glycopeptide antibiotic (Levine, 2006). 
Glycopeptides are glycosylated tricyclic or tetracyclic heptapeptides (Reynolds, 1989; Sarkar et al., 2017).The 
residue in positions 1 and 3 of the heptapeptide determine which subclass a glycopeptide belongs to. The five 
representative glycopeptides are avoparcin, vancomycin, ristocetin, complestatin and teicoplanin (Sarkar et al., 
2017). Glycopeptides target lipid II. First generation glycopeptides such as vancomycin and teicoplanin bind 
the ᴅ-Ala-ᴅ-Ala terminus (Perkins, 1969). The following generations of glycopeptides have additional 
interaction features. For example, some anchor themselves in the membrane, others can bind ᴅ-Ala-ᴅ-Lac 
(found in vancomycin-resistant bacteria) (Sarkar et al., 2017). Van der Waals bonds and five hydrogen bonds 
hold the ᴅ-Ala-ᴅ-Ala-glycopeptide complex together. The binding of glycopeptides to lipid II inhibits 
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peptidoglycan synthesis (Watanakunakorn, 1984). Vancomycin readily forms dimers in solution, which is 
thought to enhance ligand binding (Jia et al., 2013). Unlike for β-lactams, there is a lack of developed models 
of vancomycin killing. Due to vancomycin’s ability to dimerise in a variety of manners and its structural 
complexity, much of the research around it has been biochemically focused (Kahne et al., 2005). Another 
extensive body of research around vancomycin focuses on vancomycin resistance. Before the peptidoglycan 
biosynthetic pathway was even well understood, researches showed that incorporation of radiolabelled 
MurNAc and GlcNAc was inhibited after vancomycin treatment (Anderson et al., 1965; Reynolds, 1961). 
Secondary interactions of glycopepetides within the cell have also been reported, with studies showing 
interactions with cell wall metabolism members PBP2 and Atl (Leimkuhler et al., 2005; Eirich et al., 2011). The 
glycopeptides vancomycin and oritavancin have been shown to inhibit WTA biosynthesis (Singh et al., 2017). 
WTA synthesis is inhibited due to antibiotic binding of lipid II preventing lipid carrier recycling. The lipid carrier 
is required for the first steps of both peptidoglycan and WTA synthesis (Singh et al., 2017). In E. faecalis, 
vancomycin inhibits an ABC transporter potentially disrupting the uptake of nutrients (Eirich et al., 2011). 
1.13. Resistance to cell wall antibiotics 
1.13.1. Resistance, tolerance and persistence 
 
Resistance, tolerance and persistence are terms used to described different bacterial population responses to 
antibiotic treatment. Resistance is described by a change in MIC and is commonly caused by an inherited 
mutation (Brauner et al., 2016). A population resistant to a certain concentration of antibiotic is capable of 
replicating in the presence of that drug concentration. A tolerant bacterial population is able to survive 
transient antibiotic concentration and can be treated using longer exposure rather than a higher concentration 
of antibiotic (Tuomanen, Durack, & Tomasz, 1986). The difference between sensitive and tolerant strains is 
related to death kinetics rather than lack of effect, which is the case for resistance. Persistence involves only a 
sub-population of a bacterial culture. The persistent population is not killed after treatment with an antibiotic 
that effectively eliminated the rest of the population (Brauner et al., 2016). Some researchers consider 
persistence to be due to phenotypic, non-inherited changes (Balaban et al., 2004). Persistence is often 
associated with slow growth and is a form of antibiotic tolerance. 
1.13.2. β-lactam resistance 
 
There are three main mechanisms of β-lactam resistance: reduced access to the target PBPs, production of β-
lactamases and reduced binding affinity through a modified target PBP. S. aureus uses two different resistance 
mechanisms, the production of penicillinase or the production of PBP2a. Penicillinase hydrolyses β-lactams 
rendering them inactive (Sabath, 1982). Methicillin resistance in S. aureus is mediated by the staphylococcal 
chromosomal cassette mec (SCCmec). The mecA gene on SCCmec expresses PBP2a which is an additional PBP 
40 
 
with a lower affinity for β-lactams. The reduced accessibility to the active site of PBP2a leads to a decrease of 3 
to 4 orders of magnitude in the rate constant for acylation and an elevated dissociation constant for the pre-
acylation complex (Fuda et al., 2004). The presence of PBP2a allows for continued cell wall biosynthesis in the 
presence of β-lactams. PBP2a on its own is not however able to confer high levels of resistance. PBP2a is a 
class B PBP and therefore does not have transglycosylase activity and cooperated with PBP2 to synthesise 
peptidoglycan (Pinho et al., 2001). Other factors such as fem (factors essential for methicillin resistance) and 
aux (auxiliary) loci are also involved in conferring high levels of resistance in the presence of PBP2a (Chambers, 
1997). 
1.13.3. Vancomycin resistance 
 
Vancomycin resistant S. aureus strains can be split into two categories: vancomycin intermediate-resistant and 
vancomycin-resistant S. aureus (VISA and VRSA respectively). VISA strains do not have genetic elements 
carrying vancomycin resistance. These strains develop resistance through selective pressure and mutation 
during vancomycin treatment (Gardete & Tomasz, 2014). Most VISA strains develop in patients on long 
courses of vancomycin for MRSA infections. VISA strains are characterised by a thicker cell wall, decreased 
autolysis and defective daughter cell separation (Howden et al., 2010). Despite only a small increase in MIC, 
treatment failure is common in VISA infections (Gardete & Tomasz, 2014).  
VRSA strains modify the vancomycin target to achieve high levels of resistance. This modification is transposon 
mediated and was first detected in Enterococcus species, before it was transferred to S. aureus (Faron et al., 
2016). In Enterococcus, several different Van elements have been found, but so far, only VanA-type resistance 
has been found in S. aureus (Courvalin, 2006). The ᴅ-Ala-ᴅ-Ala dipeptide that vancomycin binds to is replaced 
by ᴅ-Ala-ᴅ-Lac, which decreases target affinity for vancomycin and in some cases teicoplanin making 
treatment with these drugs ineffective. The dehydrogenase VanH reduces pyruvate to ᴅ-Lac and the VanA 
ligase catalyses the bond formation between ᴅ-Ala and ᴅ-Lac (Courvalin, 2006). 
1.14. Project aims 
 
The aim of this project was to build on our existing knowledge of cell wall antibiotic mode of action to try and 
further elucidate the mechanism by which these antibiotics kill bacteria. New labels and imaging techniques 





Materials and Methods 
2.1. Growth Conditions 
2.1.1. Media 
 
All growth media was dissolved in distilled water and autoclaved at 121 °C for 15 minutes. Tryptone Soy Broth 
was used for all S. aureus experiments. Nutrient broth was used for all B. subtilis experiments.  
2.1.2. Tryptone Soy Broth (TSB) 
 
Tryptone Soy Broth (Oxoid)    30 g l-1 
1% (w/v) Bacteriological Agar (VWR) was added to make TSB Agar. 
2.1.3. Nutrient Broth (NB) 
 
Nutrient Broth (Oxoid)     13 g l-1 
2.1.4. NB Agar 
 
Nutrient Broth Agar (Sigma-Aldrich)   28 g l-1 
2.2. Antibiotics 
 
Stock solutions of antibiotics were filter sterilised, using a 0.22 µm pore size filter, before being stored at - 
20°C. To make antibiotic-containing agar plates, the antibiotic was added to molten agar cooled to below 55°C. 
All antibiotics used in this study are listed in Table 2.1.  
Antibiotic Stock solution (mg ml-1) Solvent 
Tetracycline (Tet) 5 50% (v/v) ethanol 
Minocylcine (Min) 2 dH2O 
Kanamycin (Kan) 50 dH2O 
Erythromycin (Ery) 5 95% (v/v) ethanol 
Spectinomycin (Spec) 100 dH2O 
Vancomycin 10 dH2O 
Methicillin 10 dH2O 
Oxacillin 1 dH2O 
Table 2.1. Antibiotic stock solutions and solvents. 
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2.3. Buffers & Solutions 
 
All solutions were prepared with dH2O except when stated otherwise and autoclaved where necessary. 
2.3.1. Phosphate Buffered Saline (PBS) 
 
Phosphate Buffered Saline Tablets (Sigma)   5 tablets l-1 
2.3.2. Fixative Preparation 
2.3.2.1. Preparation of 16% (w/v) paraformaldehyde 
 
100 mM sodium phosphate buffer pH 7.0: 
1 M Na2HPO4      57.7 mL 
1 M NaH2PO4      42.3 mL 
The final volume was adjusted to 1 L. 
16% (w/v) paraformaldehyde: 
100 mM sodium phosphate buffer pH 7.0  50 mL 
Paraformaldehyde     8.0 g 
The paraformaldehyde was added to 100 mM sodium phosphate buffer (pH 7.0), heated to 60°C and mixed. 
While heat and stirring were maintained, NaOH (≥ 5 M) solution was added dropwise until the solution 
cleared. The solution was stored at 4°C for up to 3 months. 
2.3.2.2. Fixative 
 
16% (w/v) paraformaldehyde    0.5 mL 
PBS       2 mL 
2.3.3. Click-iT® reaction buffer mix 
 
The reaction buffer components were purchased from Molecular Probes and made up as per their 
instructions. 
Click-iT® cell reaction buffer    440 µL 
100 mM Copper (II) sulphate    10 µL 
Click-iT® cell additive     50 µL 
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2.4. Chemicals & enzymes 
 
Stock Solution Concentration Solvent Storage 
Di-peptide (3-azido-ᴅ-alanine- ᴅ-
alanine) 
100 mM DMSO -20°C 
TADA (Tetramethylrhodamine-3-
amino-ᴅ-alanine) 
100 mM DMSO -20°C 
dark 
ADA (3-azido-ᴅ-alanine) (Iris 
Biotechnology) 
100 mM DMSO -20°C 
NHS ester Alexa Fluor™ 555 
(Molecular Probes) 
0.5 mg ml-1 DMSO -20°C 
dark 
NHS ester Alexa Fluor™ 405 
(Molecular Probes) 
0.5 mg ml-1 DMSO -20°C 
dark 
WGA Alexa Fluor™ 594 (Molecular 
Probes) 
1 mg ml-1 dH2O -20°C 
dark 
Alkyl Atto 488 1 mg ml-1 DMSO -20°C 
dark 
Alkyl Alexa Fluor™ 594 (ThermoFisher) 0.5 mg ml-1 DMSO -20°C 
dark 
14C-GlcNAc (Hartmann analytic) 250 µCi in 2.5 ml N/A 4°C 




For small volumes, Eppendorf Centrifuge 5418 was used. It has a max speed of 21,130 g and max volume of 2 
mL. For larger volumes, the Sigma 4K15 centrifuge was used, which takes tubes up to 50 mL and has a max 
speed of 21,040 g. 
2.5.2. Spectrophotometer 
 




2.6. Bacterial strains and growth 
2.6.1. S. aureus strains 
 
The S. aureus strains used in this study are listed in Table 2.3. Strains were stored in Microbank beads at - 80°C 
for long term storage. For use, strains were grown on TSB agar plates containing relevant antibiotics when 
they were required to maintain resistance marker selection. Plates were stored for up to two weeks at 4°C. To 
carry out experiments in liquid culture, 10 mL of TSB medium in a 25 mL universal tube was inoculated with a 
single colony and grown overnight at 37°C on a rotary shaker (250 rpm). Except specified otherwise, 50 mL of 
TSB medium in a 250 mL conical flask was inoculated with the overnight culture to an OD600 of 0.05 and grown 
to early exponential phase (OD600 0.2-0.3) at 37°C on a rotary shaker (250 rpm). 
Strain Genotype Source 
S. aureus SH1000 Functional rsbU+ derivative of 
8325-4 
(Horsburgh et al., 2002) 
S. aureus SH1000 sagA sagA::tetL; TetR  
S. aureus SH1000 scaH scaH::tetM; TetR  
S. aureus SH1000 sagB sagB::kan; KanR  
S. aureus SH1000 atl atl::pAZ106; EryR  
S. aureus SH1000 atl sagA 
sagB 
atl::pAZ106 sagA::tetK sagB::kan; 
EryR, TetR, KanR 
(Wheeler et al., 2015) 
S. aureus SH1000 atl sagA 
scaH 
Atl::spc sagA::tetK scaH::tetM; 
SpecR, TetR, MinR 
(Wheeler et al., 2015) 
S. aureus SH1000 sagA sagB 
scaH 
sagA::tetL sagB::kan scaH::tetM; 
TetR, KanR, MinR 
(Wheeler et al., 2015) 
S. aureus SH1000 atl sagB 
scaH 
atl::pAZ106 sagB::kan 
scaH::tetM; EryR, KanR, TetR 
(Wheeler et al., 2015) 
S. aureus SH1000 tarO tarO::ery/lyn, EryR  
Table 2.3. S. aureus strains, genotype and source. 
2.6.2. B. subtilis strains 
 
B. subtilis strains used in this study are listed in Table 2.4. For long-term storage, strains were kept in Microbank 
beads stored at - 80°C. Strains were grown on NB agar plates for short-term storage and stored for up to 5 
days at room temperature. Overnight cultures consisted of 50 mL NB medium in a 250 mL conical flask 
inoculated with a single colony. Overnight cultures were grown at 37°C on a rotating shaker (250 rpm).  
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A preculture was carried out before all B. subtilis experiments. For the preculture, 50 mL NB media in a 250 mL 
conical flask was inoculate with the overnight to an OD600 of 0.01 and grown up to an OD600 of 0.6 at 37°C on a 
rotary shaker (250 rpm). The preculture was then used to inoculate 50 mL NB in a 250 mL conical flask to an 
OD600 of 0.05. The culture was then grown at 37°C on a rotary shaker (250 rpm) to early exponential phase. 
Strain Genotype Source 
B. subtilis 168 HR HR trpC2  
Table 2.4. B. subtilis strain, genotype and source. 
2.7. Killing assays 
2.7.1. MIC 
 
To determine the minimum inhibitory concentration (MIC) of a compound, it was serially diluted in 10 mL of 
growth media (TSB for S. aureus strains, NB for B. subtilis strains) in 50 mL universal tubes. The universal tubes 
containing 10 mL growth media and different concentrations of the compound were inoculated with overnight 
culture to an OD600 of 0.05 and were grown at 37°C on a rotary shaker (250 rpm) for 24 hours. The OD600 of 
each tube was measured after 24 hours and the MIC was set as the lowest concentrations at which no growth 
was observed. 
2.7.2. CFU killing curves 
 
50 mL of media (TSB for S. aureus, NB for B. subtilis) in a 250 mL conical flask was inoculated from an overnight 
culture for S. aureus or a preculture for B. subtilis to an OD600 of 0.05 and incubated shaking (250 rpm) at 37 °C 
until early exponential phase was reached (OD600 0.2-0.3). The antibiotic was then added for a final 
concentration of 10 x MIC. 100 µL samples were taken at different time-points, washed and resuspended in 
PBS to eliminate any antibiotic. Samples were then serially diluted and were either spotted (5 µL spots) in 
three repeats onto agar plates or spread (50 µL of sample) onto TSB or NB Agar plates using glass beads. Plates 
were incubated overnight at 37°C. The number of colonies were then counted, and the CFU/mL of the original 
sample was calculated. 
2.8. Labelling 
2.8.1. Fluorescent ᴅ-amino acid labelling 
 
Three different types of fluorescent ᴅ-amino acids were used: di-peptide with an azide linker, ADA with a 
fluorescent probe already attached and ADA with an azide linker. The two first in this list are not commercially 
available and were synthesised by members of Dr. Simon Jones’ research group in the Chemistry Department 
at the University of Sheffield. ADA was purchased from Iris Biotech.  
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Cells were grown to early exponential phase. A 1 mL sample was removed and added to 10 µL of 100 mM 
FDAA in a 1.5 mL eppendorf and placed at 37°C shaking for 5 minutes.  Samples were centrifuged and the 
pellets were washed once with PBS ready for further experimental use. 
For samples where di-peptide and ADA with an azido group were used, an alkaline-containing fluorescent dye 
was attached using the Click-iT® reaction. The Click reaction is carried out on samples after fixation (2.3.2.2). 
Cells were incubated with 0.5 mL Click-iT reaction buffer mix and 10 µL alkyne fluorescent dye for 30 minutes 
on a rotator at room temperature. 
2.8.2. NHS Ester labelling 
 
1 mL of sample was taken from the desired culture and fixed according to the protocol described in 2.3.2.2. 
For SIM imaging, pellets of fixed samples were resuspended in 300 µL of PBS and 20 µL of 0.5 mg/mL NHS 
ester stock. Samples were incubated on a rotator at room temperature for 30 minutes before being washed 
and prepared for imaging. 
2.8.3. WGA labelling 
 
1mL of sample was taken from the desired culture and fixed. Samples were resuspended in dH2O and 25 µL 1 
mg/mL WGA stock and 25 µL 1M calcium chloride solution were added. Samples were incubated at 37°C for 5 
minutes before being washed and prepared for imaging. 
2.9. Fluorescent microscopy 
2.9.1. Resolution limited microscopy 
 
Sample preparation 
After fixation and required labelling, samples were washed and diluted in dH2O. The appropriate dilution was 
estimated by eye. 5 µL of the sample was applied to a poly-l-lysine slide (Sigma) and left to air-dry. The slide 
was then washed with dH2O and dried using nitrogen gas. 5 µL PBS was used to mount a coverslip, which was 
then sealed with nail polish.  
Microscopy 
Samples were imaged using the Nikon dual-cam microscope in the Wolfson Light Microscopy Facility at the 
University of Sheffield. This microscope consists of a Nikon Ti inverted microscope fitted with a Lumencor 
SpectraX light engine (395, 440, 470, 508, 561 & 640 nm) and several emission filters (DAPI, GDP, RFP, Cy5 and 
Quad of each of the previous filters). Images are acquired using a 100x PlanApo (1.4 NA) oil objective, 1.518 RI 




Images were processed using fiji, a software based on ImageJ 1.52i. Maximum intensity projections were made 
of images for presentation in this thesis.  
2.9.2. Structured illumination microscopy 
 
Coverslip preparation 
For SIM imaging, samples were mounted onto high precision coverslips (No. 1.5H, 22 x 22 nm, 170±5 µm, 
Marienfeld). Before mounting of the bacterial sample, the coverslips were washed by sonication in 1 M KOH 
for 15 minutes. The coverslips were then rinsed and incubated for 30 minutes at room temperature in 2 mL 
poly-l-lysine (Sigma). After poly-l-lysine coating, the coverslips were washed and dried using nitrogen. 
Sample preparation 
The bacterial sample was appropriately diluted in dH2O and 5 µL of the sample was applied to a poly-l-lysine 
coated high precision coverslip. The sample was dried on using nitrogen gas. 5 µL SlowFade® Diamond 
Antifade (Molecular Probes) was used to mount the coverslip (sample side down) onto a poly-l-lysine coated 
slide. Nail polish was used as a sealant.  
Microscope 
Samples were imaged using the Deltavision/GE OMX SIM (v. 4) in the Wolfson Light Microscopy Facility at the 
University of Sheffield. This SIM is fitted with 4 laser lines (405 nm, 488 nm, 568 nm, 642 nm) and four filter 
sets (436/31, 528/48, 609/37, 683/40). Images were acquired using 1.518 RI oil and a 60x 1.42 oil 
planapochromat lense. Z steps between slices were 0.125 nm. Images were reconstructed using SoftWoRx (v. 
6.1.3). 
Image rendering 
After reconstruction, a macro (Dr. Christa Walther, unpublished) was used to threshold images in an 
automated manner (same thresholding process as can be found and done manually in the SIM check plugin). 
This macro is run using fiji. The use of fourier transformation in image reconstruction generated negative 
intensity values. The thresholding process puts all grey level bins below 0 into the 0 bin. The macro also 
converts 36-bit grey level images into 16-bit grey level images for easier handling. When several fluorescent 
channels were present, false colours were applied and composite images were made. Maximum intensity 
projections of images are presented in this thesis. 
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2.10. Cell measurements 
2.10.1. Cell volume estimation 
 
Methodology adapted from (Zhou et al., 2015). 
Cell volume estimations were carried out on SIM images of NHS Ester labelled cells. In ImageJ, an average 
intensity Z project stack was made of the sample images. This projection was used for the following analysis. 
To ensure accuracy, measurements were done on cells in clusters of 4 or less. A line was drawn through the 
long axis of the cell and a fluorescence profile was generated. The distance between peaks was measured to 
generate a diameter measurement. The process was repeated at a 90-degree angle to the previous line. From 




× 𝜋 × 𝑅1 × 𝑅22, generating an estimated cell volume. This was carried out on 100 cells 
for each sample. 
2.11. Electron Microscopy 
 
After PFA fixation, samples were chemically fixed by resuspension in 2.5% glutaraldehyde overnight at 4°C. A 
secondary fixation was carried out with 2% aqueous osmium tetroxide for 2 hours at room temperature. The 
cells were then washed before being resuspended in progressively higher concentrations of ethanol to 
dehydrate them. Cells were first resuspended in 75% ethanol for 15 minutes, then 95% ethanol for 15 minutes, 
then 100% ethanol for 15 minutes, and finally 100% dried ethanol for 15 minutes. Cells were then 
resuspended in propylene oxide for 15 minutes after which the cells were transferred to a glass vial. Cells were 
incubated shaking at 2 rpm overnight in a 50/50 mix of propylene oxide/epon resin. Cells were then further 
infiltrated and embedded in epon resin and the label was added. The resin was polymerised for 2-3 days at 
60°C. The blocks were sectioned with an utramicrotome at room temperature and post stained with aqueous 
3% uranyl acetate and Reynolds lead citrate. The sections were imaged by transmission electron microscopy 
(TEM). 
2.12. Radioactive incorporation 
 
Cells were grown to the desired growth phase and 1 mL of cell culture was added to 2.5 μL of 14C-GlcNAc in a 
1.5 mL eppendorf, for a final concentration of 5 μM 14C-GlcNAc. The sample was incubated shaking at 37 °C for 
5 minutes. The cells were then incubated with 1 mL ice-cold 10% (w/v) trichloroacetic acid (TCA) on ice for 1 
hour. Samples were filtered through glass microfibre filters (Whatman) with 25 mL of 5% (w/v) TCA. The 
sample can then be found on the filters and any non-incorporated radioactive material will have been washed 
off. Filters were immersed in 10 mL Perkin Elmer Ultima Gold® scintillation fluid. Disintegrations per minutes 
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(DPM) were measured using the Packard Liquid Scintillation Analyzer Model Tri-Carb 31007R with a count time 







The effect of β-lactam antibiotics on S. aureus 
3.1. Introduction 
 
β-lactams target the cell wall synthesis machinery by binding to PBPs and inhibiting the transpeptidation step 
of peptidoglycan synthesis. A large body of research has tried to understand the molecular pathway to cell 
death after antibiotic treatment. Peter Giesbrecht developed a model where S. aureus dies upon attempting to 
initiate it’s second cell division cycle after addition of the antibiotic (Giesbrecht et al., 1998). More recent 
research suggested that induction of oxidative stress leads to β-lactam killing (Wang & Zhao, 2009). The 
Bernhardt group has developed a model whereby cells die due to resource depletion after a futile cycle of 
peptidoglycan synthesis and hydrolysis (Cho et al., 2014). This has created a confusing picture with several 
different competing models. A more in-depth presentation of previous work on the action of β-lactams can be 
found in the general introduction to this thesis (1.11). 
3.1.1. S. aureus cell cycle and peptidoglycan dynamics 
 
S. aureus divides sequentially in three orthogonal planes, possibly using peptidoglycan architecture to guide its 
next division plane (Turner et al., 2010; Tzagoloff & Novick, 1977). Peptidoglycan synthesis occurs in a non-
uniform manner, mainly at the septal annulus but also all across the cell (Lund et al., 2018; Pinho & Errington, 
2003). During division, peptidoglycan is inserted in a region across the septum (Lund et al., 2018). The leading 
edge of the septum is thinner than the lagging edge, giving a large surface area for synthesis. Once the septal 
annulus is closed, further incorporation forms a septum of uniform width before cell scission occurs. Once the 
septum is completed, peptidoglycan hydrolases, including Atl, hydrolyse the cell wall at the septal plane 
(Komatsuzawa et al., 1997). Daughter cells then pop apart on a millisecond time-scale (Zhou et al., 2015). After 
cell division, the peptidoglycan is remodelled by hydrolases to form the prolate spheroid morphology of S. 
aureus (Zhou et al., 2015). This suggests that both peptidoglycan synthesis and peptidoglycan hydrolysis are 
required for normal cell growth (Wheeler et al., 2015).  
Peptidoglycan synthesis can be split into three main stages. First, the precursors (UDP-MurNAc and UDP-
GlcNAc) are synthesised in the cytoplasm (Typas et al., 2012). Next, the muropeptides are assembled, forming 
lipid II, and are flipped across the membrane. Finally lipid II is polymerised into glycan chains that are then 
inserted into the existing peptidoglycan (Typas et al., 2012). Penicillin-binding proteins (PBPs) catalyse the 
polymerisation of the glycan strands and crosslinking of the glycan strands (transglycosylation and 
transpeptidation respectively) during synthesis (Sauvage et al., 2008). Transglycosylation can also be catalysed 
by several other components: Mgt, SgtA, FtsW & RodA (Emami et al., 2017; Reed et al., 2011; Taguchi et al., 
2019). S. aureus has four native PBPs: PBP1, PBP2, PBP3 and PBP4 (Canepari et al., 1985). PBP1 and PBP2 are 
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essential and comprise the minimum peptidoglycan synthesis machinery required for S. aureus to grow (Reed 
et al., 2015).  PBP2 is a class A HMW PBP with both transpeptidase and transglycosylase activity. PBP1, PBP3 
and PBP4 only have transpeptidase activity (Scheffers & Pinho, 2005).  
After cell division, the newly synthesised septum is remodelled by glucosaminidases. S. aureus has four 
glucosaminidases, SagA, SagB, ScaH and Atl, that are collectively essential (Wheeler et al., 2015). 
Glucosaminidases cleave the bond between the N-acetylglucosamine and N-acetylmuramic acid residue of the 
glycan backbone, creating the shorter glycan strands characteristic of S. aureus peptidoglycan (Boneca et al., 
2000). All four glucosaminidases play a role in cell enlargement and normal cell morphology although lack of 
SagB has the biggest impact on cell morphology, with cells remaining smaller and more hemispherical 
(Wheeler et al., 2015).  
3.1.2. Methods used to study β-lactams 
 
To study the effect of antibiotics, measuring killing is an important step. Optical density (OD) measurements 
give us a measure of culture turbidity, which is correlated to growth. However, OD is not a very accurate 
measure for cell death as the rate of cell lysis can affect measurements. A more accurate way of measuring cell 
viability after antibiotic treatment is to use colony forming units (CFUs). CFUs are a commonly used method to 
determine the number of live cells present in a culture at any given time. The measure tells us how many units 
(i.e. bacteria) able to form a colony on an agar plate were present in the culture. The change in the number of 
CFU in a culture over time is used to measure growth and death.  
Imaging has played a role in furthering our understanding of the action of β-lactams. Electron microscopy has 
been used extensively to study the effect of β-lactams. The most extensive model of β-lactam killing developed 
by Peter Giesbrecht was based on EM images of S. aureus after penicillin treatment (Peter Giesbrecht et al., 
1998). EM offers higher resolution images than fluorescence microscopy. 
Mutants with altered responses are one of the most common tools used to study antibiotics. Interest is taken 
in strains that exhibit increased resistance, persistence or tolerance to an antibiotic (Dengler et al., 2013; 
Germain et al., 2013; Kaspy et al., 2013). These studies can give us insight into the mode of action of antibiotics 
but mainly help elucidate changes that lead to resistance. The effect of antibiotics on gene expression has also 
been studied (Mwangi et al., 2013). In the case of β-lactams, most studies looking at gene expression focus on 
changes in expression of factors relaying resistance (eg. expression of genes encoding β-lactamases). 
Since β-lactams target the cell wall metabolism, studies have used methods to measure peptidoglycan 
synthesis. The existing methods to quantify peptidoglycan synthesis are described in detail later in the 
introduction to this chapter. 
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3.1.3. Structured illumination microscopy 
 
The resolution of conventional light microscopy is limited by the diffraction of light through the objective of 
the microscope (Huang et al., 2010). Light converges into a focal point, and this focal point is of finite size due 
to diffraction. With conventional microscopy, it is not possible to differentiate between two fluorescent 
molecules located within the focal point. The resolution limit of conventional light microscopy is ~250 nm in 
the lateral dimension and ~550 nm in the axial dimension (Huang et al., 2010).  
A new range of super-resolution microscopy techniques has been developed allowing imaging at resolutions 
well beyond those of diffraction limited microscopy (Huang et al., 2010). The new techniques can distinguish 
two molecules within a diffraction-limited region by using the physical properties of fluorescent probes. The 
main super-resolution microscopy techniques are stimulated emission depletion microscopy (STED), 
structured illumination microscopy (SIM), stochastic optical reconstruction microscopy (STORM) and 
fluorescence photoactivation localization microscopy (FPALM). 
A more detailed explanation of SIM will be presented here as it was the chosen super-resolution microscopy 
technique for this project. In SIM, a known regular illumination pattern is juxtaposed over the sample. The 
unknown sample structure and the known illumination pattern generate a pattern called moiré fringes. The 
unknown sample structure can be computationally extracted from the moiré fringes (Gustafsson, 2005; 
Heintzmann et al., 2002). The pattern is rotated at several different angles over the sample, to give a complete 
rendering of the sample. A resolution of < 50 nm can be obtained with SIM using bright and stable 
fluorophores (Gustafsson, 2005). One of the main advantages of SIM is that it does not require fluorophores 
with particular photo-properties – the fluorophores commonly used for conventional fluorescence microscopy 
can be used with SIM. However, due to the large number of pictures taken of the sample to render one image, 
bright and photostable fluorophores are required for high quality images. 
3.1.4. Labelling of the bacterial cell surface 
 
Several labels are available that can be used to visualise the bacterial cell surface. These include fluorescent 
NHS ester and wheat germ agglutinin (WGA). 
N-hydroxysuccinimide (NHS) ester (aka. succinimidyl ester) binds to primary amines of proteins and other 
amine-containing molecules. On the cell surface it can bind to peptide side chains of peptidoglycan as well as 
surface proteins. A large range of fluorophores conjugated to NHS Ester can be found commercially, making it 
a versatile tool for cell surface labelling.  
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WGA is a lectin extracted from wheat that serves as a barrier to insects, yeast and bacteria. WGA binds GlcNAc 
making it an effective label of gram-positive bacteria cell wall when conjugated with a fluorophore. WGA and 
fluorophore conjugates are commercially available. 
3.1.5. Labelling peptidoglycan incorporation 
 
Over the last 30 years different techniques have been developed to help further our understanding of 
peptidoglycan synthesis. The first studies that sought to investigate peptidoglycan synthesis used uranyl 
acetate staining of thin cell sections imaged by EM or autoradiography of radiolabelled sacculi (Merad et al., 
1989). Both of these methods use sacculi rather than live cells, limiting their usefulness.  
The first method developed using the incorporation of alternate ᴅ-amino acids into the peptide side chain was 
developed in E. coli (de Pedro et al., 1997). The growth media was supplemented with ᴅ-cysteine which is 
incorporated as the terminal ᴅ-amino acid of the peptide side chain by exchange reaction in the periplasm. ᴅ-
cysteine contains thiol groups that are then detected by immune-detection and labelled for fluorescence or 
electron microscopy. Again, this method is limited to use in sacculi.  
More recently, fluorescent vancomycin was developed as a tool to label new peptidoglycan (Daniel & 
Errington, 2003). Vancomycin binds the ᴅ-ala-ᴅ-ala motif at the end of the peptide side chain. In most species, 
the terminal ᴅ-ala-ᴅ-ala is rapidly processed by crosslinking of the peptide side chain or by hydrolysis. 
Vancomycin can therefore only bind nascent peptidoglycan and can be used as a probe to locate newly 
synthesised peptidoglycan. S. aureus has low carboxypeptidase activity, leaving terminal ᴅ-ala-ᴅ-ala motifs in 
mature peptidoglycan (Scheffers & Pinho, 2005). To allow for the use of fluorescent vancomycin in S. aureus, 
the cells must first be grown in the presence of ᴅ-serine, which is incorporated into the terminus of the 
peptide side chain instead of ᴅ-ala. The cells are then briefly incubated in the presence of ᴅ-ala, allowing for 
labelling of the new peptidoglycan with vancomycin. This method, although an advancement, does not label 
live cells. 
Fluorescent ᴅ-amino acids (FDAAs) developed by the Van Nieuwenhze group allow us to carry out live cell 
labelling of peptidoglycan synthesis (Kuru et al., 2012). FDAAs are incorporated into position 4 or 5 of the 
peptide side chain. Around the same time, a second group developed ᴅ-amino acid probes with azide and alkyl 
groups, allowing researches to use click chemistry to attach a fluorescent dye of their choice (Siegrist et al., 
2013).  
There are thought to be two possible incorporation pathways for FDAAs: precursor synthesis in the cytosol and 
periplasmic modification of mature peptidoglycan (Cava et al., 2011). To be incorporated into nascent 
peptidoglycan, the single ᴅ-alanine is joined into a ᴅ-alanyl-ᴅ-alanine dipeptide by the ᴅ-alanine-ᴅ-alanine 
ligase (Ddl). The dipeptide is then added to the growing peptide side chain via MurF. To bypass the question of 
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whether observed incorporation represents new peptidoglycan or post-synthesis modification, a ᴅ-alanyl-ᴅ-
alanine (or “dipeptide”) label was developed (Liechti et al., 2014). The dipeptide is incorporated into 
peptidoglycan precursors via MurF. In S. aureus all three probes mark regions of new peptidoglycan 
incorporation (Lund et al., 2018).  
Methods are also available to incorporate modified backbone sugars. Peptidoglycan incorporation can be 
measured by incorporation of 14C-GlcNAc (Maki et al., 2001). This method allows quantification of 
incorporation but not for localisation. Most recently, Catherine Grimes’ group developed a method by which 
NAM derivates can be incorporated during peptidoglycan synthesis (Liang et al., 2017). However, this novel 
technique requires genetic manipulation of the organism.  
3.1.6. Aims of this chapter 
 
• Investigate the effect of β-lactams on S. aureus and B. subtilis 
• Establish death kinetics 
• Study the effects of antibiotics on cell morphology 
• Establish the effect of β-lactams on macromolecular synthesis 
3.2. Results 
3.2.1. Killing Dynamics 
 
Methicillin was used as the representative β-lactam as it was developed specifically for treating S. aureus 
infections. Oxacillin was used to confirm findings. 
MICs were measured using a serial dilution method. Cultures were grown overnight in the presence of 
different concentrations of antibiotics. After 24 hours, culture OD600 was measured and the MIC determined. 
The MIC of methicillin against S. aureus SH1000 was found to be 4 µg/mL, and the MIC of oxacillin against S. 
aureus SH1000 was 1 µg/mL. All the experiments described here were carried out using 10 x MIC (i.e. 40 
µg/mL methicillin, 10 µg/mL oxacillin). 
Kill curves were used to assess the killing dynamics of methicillin and oxacillin. Survival was quantified by 
measuring the number of colony forming units (CFUs) at given time points after treatment. Overnight cultures 
of S. aureus SH1000 were freshly inoculated at a starting OD600 of 0.05. Cultures were grown, shaking, at 37°C, 
until they reached an OD600 of 0.2-0.3 (early exponential phase). The antibiotic was then added to the culture 
and the CFUs were measured at regular intervals for 6 hours. 
When S. aureus SH1000 is treated with methicillin, an initial increase in cell numbers was observed for the first 
30 minutes to an hour after which killing began (Figure 3.1). 90% killing was reached 5 hours after addition of 
10 x MIC methicillin to the growth media. 
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Figure 3.1. Effect of 40 µg/mL (10 x MIC) methicillin on S. aureus SH1000 cell viability. The CFU/mL was 
determined at each time-point and the data was normalised by setting the first time point as 100%. The mean 




Within 30 minutes killing was observed when S. aureus SH1000 was treated with 10 µg/mL oxacillin (Figure 
3.2). 90% killing was reached between 1.5 and 2 hours after addition of 10 x MIC oxacillin to the growth media.  
3.2.2. Cell morphology 
 
β-lactams are cell wall antibiotics inhibiting peptidoglycan synthesis. As the cell wall determines cell shape, the 
effect of β-lactams on cell morphology was investigated.  
To investigate changes in cell morphology after treatment with 10 x MIC methicillin, cells were fixed at 
different time points post-antibiotic treatment. Fixed cells were then labelled with NHS Ester 555 and imaged 
using SIM. NHS Ester is a fluorescent dye containing probe that binds amines on the cell surface, allowing 
visualisation of the cell shape. High-resolution SIM images allow insight into cell morphology dynamic after 
antibiotic treatment. Fixed cells were also imaged using EM. 
3.2.2.1. Methicillin 
 
Morphological changes could be observed within 60 minutes of treatment with 40 µg/mL methicillin (Figure 
3.3). At 60 minutes post-addition of methicillin cells with deformed, wider septa and cells with no septa were 
observed (Figure 3.3, Panel B). By 120 minutes after the addition of antibiotic some cells were grossly 
deformed. There were also many sacculi, some of which appear to have ripped at the septum (Figure 3.3, 
Panel C). 
To quantify changes to the cells, cell volume was measured. Cell volume was estimated using ImageJ 
measurements as described by Zhou et al., 2015. In a non-treated population, the mean cell volume did not 
change significantly over time. After 60 minutes of treatment with 40 µg/mL methicillin, a highly significant 
increase in the mean cell volume was observed between the untreated and treated populations (Figure 3.4). 
Fixed cells were also imaged using EM (Figure 3.5). 60 minutes after addition of 40 µg/mL methicillin to the 
growth media gross changes to the cell morphology particularly the appearance of bulging septa and wide cell 
walls were seen (Figure 3.5, Panel C). What appear to be large septa have an apparent septal plate with its 
characteristic V-shape but there is also a lesion separating it from the cytoplasmic membrane (Figure 3.5, 
Panel C). 17.4% of the cells exhibit a morphology where the cell membrane has been separated from the cell 
wall. The septal plate appears to have been hydrolysed apart into its two component parts (Figure 3.5, panel 
C). 
Four main morphologies were identified in the EM images and quantified: cells with no visible septum, cells 
with a complete septum, cells with an incomplete septum, cells with an incomplete septum that has been 
hydrolysed down the middle (split incomplete septum) (Figure 3.6). This quantification does not take into 
account whether a gap has developed between the cell membrane and the cell wall. In the untreated control,  
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Figure 3.2. Effect of 10 µg/mL (10 x MIC) oxacillin on S. aureus SH1000 cell viability. S. aureus SH1000 was 
treated with 10 µg/mL methicillin (10 x MIC). The CFU/mL was determined at each time-point and the data 
was normalised by setting the first time point as 100%. The mean and standard deviation are plotted and the 





Figure 3.3. Effect of methicillin treatment on S. aureus SH1000 cell morphology (SIM images). Cells were 
treated with 40 µg/mL methicillin (10 x MIC), fixed after 0, 30, 60 and 120 minutes of treatment and 
subsequently labelled with NHS Ester 555. Cells were imaged using the OMX SIM and maximum intensity 
projections are shown. (A) Fields of cells from each time point, as indicated. All scale bars 5 µm. (B) 
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Representative cells after 60 minutes of treatment. All scale bars 1 µm. (C) Representative cells after 120 
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Figure 3.4. Effect of methicillin treatment on S. aureus SH1000 cell volume. Cell volume was calculated from 
measurements carried out in ImageJ, on OMX SIM images of NHS Ester 555 labelled cells at different time 
points after the addition of 40 µg/mL methicillin (10 x MIC). P-values were calculated by Mann-Whitney tests. 
Whiskers extend from the minimum to the maximum values and boxes from the 25th to the 75th percentile. 







Figure 3.5. Effect of methicillin treatment on S. aureus SH1000 cell morphology (EM images). Cells were 
treated with 40 µg/mL methicillin (10 x MIC), fixed after 60 minutes of treatment and imaged by electron 
microscopy. All EM images were acquired by Lucia Lafage. (A) Field of cells from the control. Scale bar 2 µm. 
(B) Field of cells after 60 minutes methicillin treatment. Scale bar 2 µm. (C) Representative cell after 60 
minutes of treatment. Scale bar 200 nm. (D) Magnification of a cell section from a representative cell after 60 





Figure 3.6. Quantification of cell morphologies in EM images after methicillin treatment. Four morphologies 
were identified and quantified in the untreated control and after 60 minutes of treatment with 40 µg/mL 





58% of the cells do not have a septum, 23% show a complete septum and 19% of the cells have an incomplete 
septum with a normal septal plate. After an hour of treatment with 10 x MIC methicillin, 69% of the cells didn’t 
have a septum, 1% had a complete septum, 1% of the cells had a normal incomplete septum and 29% of the 
cells have an incomplete septum that had been split (Figure 3.6). 
3.2.2.2. Oxacillin 
 
After treatment with 10 µg/mL oxacillin, cells developed unusual morphologies. In Figure 3.7, a variety of 
morphologies were observed at different time points after treatment with oxacillin. At 60 minutes post-
antibiotic addition, cells with deformed septa and cells that had undergone unfinished divisions were seen 
(Figure 3.7, Panel B). After 120 minutes of treatment, more deformed morphologies were observed and there 
were many sacculi in the sample (Figure 3.7, Panel C). These morphologies resembled those observed after 
treatment with 10 x MIC methicillin.  
The same increase in cell volume that was observed after methicillin treatment, was found after treatment 
with 10 x MIC oxacillin (Figure 3.8). A significant increase in cell volume occurred as little as 15 minutes after 
the addition of oxacillin to the growth media.  
3.2.3. Quantification of peptidoglycan synthesis in the presence of antibiotics 
 
Two methods were used to measure peptidoglycan synthesis post-antibiotic treatment: 
- Fluorescent D-amino-acid (FDAA) incorporation to determine transpeptidase activity 
- 14C-GlcNAc incorporation to determine transglycosylase activity  
The FDAA incorporation experiments carried out with methicillin, were done using dipeptide. Dipeptide is a D-
ala-D-ala molecule containing an azide group, to which compatible fluorophores can be attached by click 
chemistry (Liechti et al., 2014) (2.8.1). The FDAA incorporation experiment carried out with oxacillin, was done 
using TADA, a ᴅ-alanine with a fluorophore already attached to it (Kuru et al., 2015). When grown in the 
presence of dipeptide or TADA, cells incorporate the labels into the peptide side-chains of their nascent 
peptidoglycan (Lund et al., 2018).  
The dipeptide and TADA were synthesised by Prof. Simon Jones’ group in the Department of Chemistry at the 
University of Sheffield.  
3.2.3.1. Methicillin 
 
40 µg/mL methicillin (10 x MIC) was added to the growth media of an S. aureus SH1000 culture at an OD600 of 




Figure 3.7. Effect of oxacillin treatment on S. aureus SH1000 cell morphology. Cells were treated with 10 
µg/mL oxacillin (10 x MIC), fixed after 0, 30, 60 and 120 minutes of treatment and subsequently labelled with 
NHS Ester 555. Cells were imaged using the OMX SIM and maximum intensity projections are shown. (A) Fields 
of cells from each time point, as indicated. All scale bars 5 µm. (B) Representative cells after 60 minutes of 
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Figure 3.8. Effect of oxacillin treatment on S. aureus SH1000 cell volume. Cell volume was calculated from 
measurements carried out in ImageJ, on OMX SIM images of NHS Ester 555 labelled cells at different time 
points after the addition of 10 µg/mL oxacillin (10 x MIC). P-values were calculated by Mann-Whitney tests. 
Whiskers extend from the minimum to the maximum values and boxes from the 25th to the 75th percentile. 




shaking at 37°C, for 5 minutes in the presence of 10 µL of 100 mM dipeptide. Samples were then fixed and 
labelled by click chemistry with alkyne Atto 488, which binds to the azide group of the incorporated 
dipeptides. The samples were imaged using the Nikon Dual Cam. 
In Figure 3.9 a decrease in fluorescence after antibiotic treatment was observed. The fluorescence per cell was 
quantified using image J. The fluorescence/cell was measured for 100 cells per time point (Figure 3.9 & Figure 
3.10). A statistically significant reduction in dipeptide incorporation is observed within the first 5 minutes of 
treatment. This suggests that treatment with 10 x MIC methicillin leads to an immediate reduction in 
peptidoglycan synthesis. Only residual dipeptide incorporation is observed after 15 minutes. 
Incorporation of 14C-GlcNAc can be used to measure peptidoglycan synthesis. 14C-GlcNAc is a radioactive 
derivative of GlcNAc, which the cells incorporate into their nascent glycan chains. Cells were incubated for 5 
minutes in the presence of the compound at different points after treatment with 10 x MIC methicillin. Cells 
were then fixed. The radioactivity of each sample was then measured in disintegrations per minute (DPM) per 
CFU. A significant drop in incorporation is observed after 15 minutes of methicillin treatment (p < 0.0001) 
(Figure 3.11). However, high residual levels of incorporation are observed. After 60 minutes of methicillin 
treatment mean DPM/CFU is 30% of the control sample mean DPM/CFU.  
3.2.3.2. Oxacillin 
 
Cells were treated with 10 µg/mL oxacillin (10 x MIC) and processed in the same manner as those treated with 
methicillin, as described in section 3.2.3.1. However, TADA was used as the FDAA. TADA measures both Mur-
associated synthesis and exchange reaction, however our previous data shows that dipeptide and TADA are 
equable. The samples were imaged using the Nikon Dual Cam. 
A decrease in fluorescence after treatment with 10 x MIC oxacillin was observed (Figure 3.12). This decrease 
per cell was quantified and a statistically significant reduction in TADA incorporation was observed within the 
first 5 minutes after addition of methicillin (Figure 3.13). After 15 minutes only residual levels of TADA 
incorporation were observed.  
3.2.4. Fate of newly incorporated peptidoglycan 
 
Cells were incubated in the presence of ADA for 5 minutes prior to the addition of 40 µg/mL methicillin to the 
growth media (treated samples) or incubation in fresh growth media without ADA (untreated sample). The aim 
of this experiment was to investigate the fate of the peptidoglycan newly synthesised immediately prior to 
treatment with 10 x MIC methicillin. The cells were also labelled with NHS Ester 405 to allow localisation of the 





Figure 3.9. Effect of methicillin treatment on di-peptide incorporation in S. aureus SH1000. Cells were grown 
in the presence of di-peptide for 5-minute periods after the addition of 40 µg/mL methicillin (10 x MIC). The 
newly incorporated material was subsequently labelled by click reaction with atto 488 and imaged on the 
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Figure 3.10. Quantification of the effect of methicillin treatment on di-peptide incorporation in S. aureus 
SH1000. Cells were treated with 40 µg/mL methicillin (10 x MIC) and samples were incubated with di-peptide 
for 5 minutes at different intervals after antibiotic addition. Samples were then fixed and imaged using 
identical settings. The fluorescence/cell was measured using ImageJ. P-values calculated by Mann-Whitney. 
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Figure 3.11. Effect of methicillin treatment on S. aureus SH1000 incorporation of 14C- GlcNAc. Cells were 
treated with 40 µg/mL methicillin (10 x MIC) and samples were incubated with 14C- GlcNAc for 5 minutes at 
different intervals after antibiotic addition. P-values calculated from unpaired t-tests with Welch’s correction. 




Figure 3.12. Effect of oxacillin treatment on TADA incorporation in S. aureus SH1000. Cells were grown in the 
presence of TADA for 5-minute periods after the addition of 10 µg/mL oxacillin (10 x MIC). Cells were imaged 
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Figure 3.13. Quantification of the effect of oxacillin treatment on TADA incorporation in S. aureus SH1000. 
Cells were treated with 10 µg/mL oxacillin (10 x MIC) and samples were incubated with TADA for 5 minutes at 
different intervals after antibiotic addition. Samples were then fixed and imaged using identical settings. The 








Figure 3.14. Fate of newly synthesised peptidoglycan after methicillin treatment. Cells were grown in the 
presence of ADA for 5 minutes before being washed and treated with 40 µg/mL methicillin (10 x MIC) or not. 
Cells were fixed at 0, 30 & 60 minutes after addition of methicillin or resuspension in fresh media. The 
incorporated ADA was clicked with Alexa Fluor 594 and the cells were labelled with NHS Ester 405. Maximum 
intensity projections are presented. (A) Fields of cells after 5 minutes of ADA incorporation. All scale bars 5 µm. 
(B) Fields of cells from the untreated and methicillin samples 30 minutes after ADA incorporation. All scale bars 
5 µm. (C) Representative cells 30 minutes after ADA incorporation. All scale bars 1 µm. (D) Representative cells 
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30 minutes after ADA incorporation and methicillin addition. All scale bars 1 µm. (E) Fields of cells from the 
untreated and methicillin samples 60 minutes after ADA incorporation. All scale bars 5 µm. (F) Representative 
cells 60 minutes after ADA incorporation. All scale bars 1 µm. (G) Representative cells 60 minutes after ADA 




Over 5 minutes, S. aureus SH1000 incorporated ADA mainly at the septum with some incorporation over the 
whole cell wall (Figure 3.14, Panel A). The septum is made as a diffuse ring as the annulus closes. During the 
cell cycle 5 min ADA incorporation manifests in different incorporation patterns. Septum formation is 
characterised by an initial bright ring of ADA incorporation, which coincides with the formation of the pie 
crust. Subsequently, the septal plate is synthesised, thus ADA incorporation will be seen as a ring of 
diminishing radius. All cells show incorporation around the periphery of the cells.  
3.2.4.1. Fate of newly incorporated peptidoglycan in the untreated cell population 
 
Six different cell morphologies were identified in the images 0, 30 and 60 minutes after the sample was 
washed and resuspended in ADA-free media (Figure 3.15, Panel C). The prevalence of each morphology was 
quantified at each time-point (Figure 3.15, Panel D). The model table in panel B of Figure 3.15 shows how each 
morphology can come about. Above the model cells, the cell cycle stages that lead to the morphology are 
specified. In the model, one can see how the fate of the incorporated material is different depending on which 
stage of the cell cycle it was incorporated at. The model explains the different steps leading to each observed 
pattern of ADA seen in the fluorescent images (Figure 3.14).  
After the 5 minutes of incorporation, 80% of the cells incorporated ADA primarily into their septa (Figure 3.15, 
Panel D). 10% of the cells displayed a split punctate morphology, suggesting they were at the end of septum 
formation and finished their septa with ADA before splitting. The last 10% of the cells were barely 
incorporating, suggesting they had just divided when ADA was added, and had not yet begun making a new 
septum. 
After 30 minutes, 45% of the cells had the incorporated ADA covering half of the cell and 45% of the cells had 
just divided (split punctate + split donut). This shows the cells are progressing through the cell cycle as can be 
seen in the model figure in panel B. After 60 minutes, 60% of the cells had the incorporated ADA in only a 
quarter of their cell wall (Figure 3.15, Panel D).  
3.2.4.2. Fate of newly incorporated peptidoglycan after methicillin treatment 
 
After 30 minutes of treatment with 40 µg/mL (10 x MIC) methicillin the ADA was still mainly localised at the 
septum in over 50% of the cells, as opposed to less than 10% of the cells after 30 minutes in the untreated 
sample (Figure 3.16). 25% of the cells show the split punctate ADA pattern, which was the same as the 
untreated sample after 30 minutes. These cells completed their septa with ADA and split within the first 30 
minutes of treatment (Figure 3.15, Panel B). Approx. 23% of the cells had a whole cell ADA pattern after 30 








Figure 3.15. Quantification and model of the fate of newly synthesised material over 60 minutes. (A) Cells 
were grown in the presence of ADA for 5 minutes before being washed and resuspended in media without 
ADA. Cells were fixed 0, 30 and 60 minutes after resuspension. The incorporated ADA was clicked with Alexa 
Fluor 594 and the cells were labelled with NHS Ester 405. Samples were imaged on the SIM and observed ADA 
patterns were quantified. (B) Model of the fate of incorporated ADA. Cyan represents incorporated ADA, black 
represents unlabelled peptidoglycan. Above each model cell is the stage of the cell cycle and below each 
model cell is the pattern of the cell as shown in panel C. (C) Representative cells of each observed pattern. 
Composite images where cyan is ADA Clicked with Alexa Fluor 594 and magenta is NHS Ester 405 labelling. 
Scale bars 1 µm. (D) The prevalence of each morphology was quantified in a population of approx. 100 (n as 
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Figure 3.16. Quantification of the fate of newly synthesised material after methicillin treatment. The 
prevalence of each cell morphology (Figure 3.15) was quantified in a population of approx. 100 (n indicated in 




After 60 minutes of methicillin treatment the observed ADA patterns are the same as those observed after 30 
minutes of treatment: septum, split punctate and whole cell. However, the prevalence of each morphology 
changed (Figure 3.16). In 50% of the cells, the newly incorporated peptidoglycan was still located at the 
septum. 17% of the cells still displayed a split punctate ADA pattern and 33% displayed a whole cell ADA 
pattern.  
In the treated samples, at 30 and 60 minutes, no split donut, half or quarter cell morphologies were observed 
(Figure 3.16). 
3.2.5. The effect of methicillin treatment on B. subtilis 
3.2.5.1. Killing dynamics 
 
The MIC of methicillin against B. subtilis 168 HR was established using a standard serial dilution method. The 
MIC of methicillin against B. subtilis was found to be 0.25 µg/mL. B. subtilis 168 HR died rapidly after the 
addition of 2.5 µg/mL methicillin to the growth media (Figure 3.17). 90% killing was reached between 30 
minutes and 1 hour after treatment with 10 x MIC methicillin. 
3.2.5.2. Morphological changes 
 
B. subtilis was labelled with WGA at different time points post antibiotic treatment and imaged using the SIM. 
WGA was used rather than NHS ester, because a large portion of the cells showed intracellular labelling when 
labelled with NHS ester. Several different fixing and labelling protocols were tested showing no improvement 
(results not shown). Good quality labelling was obtained with WGA, so this label was used for all B. subtilis cell 
surface labelling.  
30 and 60 minutes after the addition of 2.5 µg/mL methicillin (10 x MIC) to the growth media, there were 
visible changes to the morphology of some cells (Figure 3.18). More sacculi were present in the samples, many 
of which appear to have ripped at the septum. Many cells had deformed, wider septal regions. Cell length and 
width were measured using ImageJ. Cells were only described as individuals if complete septa were observed 
by z stack analysis of the fluorescent images. After 60 minutes of treatment with 10 x MIC methicillin, no 
significant change in cell length was observed and a small significant increase in cell width was observed 
(Figure 3.19). 
3.3. Discussion 
3.3.1. Morphological changes 
 
Oxacillin and methicillin were both bactericidal for S. aureus although oxacillin killed faster and at lower 




Figure 3.17. Methicillin killing of B. subtilis. B. subtilis 168 HR was treated with 2.5 µg/mL methicillin (10 x 
MIC). The CFU/mL was determined at each time-point and the data was normalised by setting the first time 
point as 100%. The mean and standard deviation are plotted. This experiment was done in triplicate. 
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Figure 3.18. Effect of methicillin on B. subtilis 168 HR morphology. Cells were treated with 2.5 µg/mL 
methicillin (10 x MIC), fixed after 0, 15, 30 and 60 minutes and subsequently labelled with WGA 594. Cells 
were imaged using the OMX SIM and maximum intensity projections are shown. (A) Fields of cells from each 
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time point, as indicated. All scale bars 5 µm. (B) Representative cells after 60 minutes of treatment. All scale 
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Figure 3.19. The effect of methicillin on B. subtilis 168 HR cell length and width. Cell length and width were 
measured in image J using images acquired on the OMX SIM of WGA labelled B. subtilis fixed at different time 
points after the addition of 2.5 µg/mL methicillin (10 x MIC). The error bars represent standard deviation. P-
values were calculated by two-tailed t-test with Welch’s correction.  
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observed (Figure 3.4 & Figure 3.8). This could be due to peptidoglycan synthesis and peptidoglycan hydrolysis, 
which are both required for normal cell growth (Wheeler et al., 2015). However, FDAA and 14C-GlNAc 
incorporation data showed that methicillin and oxacillin treatment halted peptidoglycan synthesis almost 
immediately after addition of the antibiotics to the culture (Figure 3.10, Figure 3.11 & Figure 3.13). These 
results would suggest that the increase in cell volume observed after β-lactam treatment is due to continued 
hydrolysis of the cell wall after incorporation has been halted. 
Unusual morphologies were observed in images of NHS Ester-labelled cells after antibiotic treatment. Some 
cells had deformed septa, others appeared to have a “dumbbell” shape (Figure 3.3, Panels B & C). The 
dumbbell shapes observed could be due to attempts to split with incomplete septa. The wider and deformed 
septa observed in the NHS Ester labelled cells treated with 10 x MIC methicillin could be explained by 
hydrolysis of the existing septa, creating loose material at the septum. This is supported by observations made 
in the EM images of methicillin-treated cells (Figure 3.5). After 60 minutes of treatment with 10 x MIC 
methicillin, the septal plates have been hydrolysed into two halves along their length. This suggests that the 
hydrolases located at the septum, that are involved in cell division, are still active after treatment with 
methicillin. Only 1% of the cells have a complete septum after treatment with methicillin, compared to 23% in 
the untreated control, this can also be explained by the continued action of cell division hydrolases, combined 
with the halt in peptidoglycan synthesis which inhibits the completion of partially formed septa after 
methicillin treatment (Figure 3.6). In all the samples, a high proportion of the cells presented with no septum. 
This can be explained by the fact that in EM, a single slice of the cell has been imaged, and many cells with 
septa, can easily appear to have no septum if the imaged slice happens to not be in the right plane. 
A separate quantification was carried out to measure the number of cells where the cell membrane appeared 
to have separated from the cell wall. After 60 minutes of methicillin treatment, 17.4% of the cells had a gap 
between the cell wall and the cell membrane somewhere along the periphery of the cell. In gram-positive 
organisms there is a periplasm-like space between the cell membrane and the cell wall, which can be called 
the exoplasm (Matias & Beveridge, 2006). The observed gap between the cell wall and the membrane may be 
due to excessive material in the exoplasm or it could be explained by a loss of osmotic pressure and pulling 
away of the membrane from the cell wall. 
3.3.2. Peptidoglycan incorporation and fate 
 
A significant decrease in FDAA incorporation was observed within the first 5 minutes of treatment with 10 x 
MIC methicillin and oxacillin and only baseline levels of incorporation remained within 15 minutes. This is not 
an unexpected result as β-lactams bind penicillin-binding proteins, which are responsible for crosslinking of 
peptidoglycan. This questions the hypothesis that the cells continue making peptidoglycan for at least a 
complete cell cycle after treatment (Giesbrecht et al., 1998). Septal expansion is observed, but this is not due 
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to further incorporation of peptidoglycan. Our images show that the septum itself still maintains its thin V-
shape but is surrounded by a bulbous layer of amorphous material or the membrane has pulled away from the 
cell wall. 
The fate of newly incorporated peptidoglycan in the untreated sample concurs with our current understanding 
of S. aureus cell division (Lund et al., 2018; Monteiro et al., 2015). S. aureus cells split into two daughter cells at 
the septum, hydrolysis remodels the new cell wall (previously the septum of the mother cell), remodelling it to 
give the cell its typical spheroid shape. They divide sequentially in three orthogonal planes, which means that 
after each division cycle, one half of the cell is composed of new peptidoglycan. The other half of the cell will 
have 1 quarter from the previous cycle, one eight from the division cycle before that, etc… In the images 
presented, we see the labelled peptidoglycan occupy a half and then a quarter of the cell wall as the cells 
progress through one, then two cell cycles (Figure 3.15).  
Investigation of the fate of newly incorporated peptidoglycan after antibiotic treatment, showed that cells are 
not progressing through the cell cycle after treatment with methicillin. No half, quarter or split donut cells 
were seen in the treated sample. The change in proportion of the observed morphologies in the treated 
samples over time, could be explained by hydrolysis of the cell wall. Some of the cells will have finished their 
septum during the 5 minutes of ADA incorporation and then split over the following 30 minutes, leading to the 
higher number of cells exhibiting a “Split – punctate” pattern. Cells that had just split prior to antibiotic 
treatment have hydrolysed the new cell wall making the incorporated ADA more disperse and leading to the 
increase in “whole cell” morphology. Hydrolases may also have hydrolysed septa that had just begun forming 
during the 5 minutes of ADA incorporation, with the material then occupying a larger area, the cells would 
show a “whole cell” morphology by 30 or 60 minutes after treatment. A punctate pattern has also appeared at 
the septum of many cells. This pattern may be due to the hydrolysis of the septal plate into two halves, as seen 
in the EM images (Figure 3.5 & Figure 3.16). 
After methicillin treatment, some residual incorporation of 14C-GlcNAc was observed (Figure 3.11). Several 
explanations are possible for this. Cells could be accumulating precursors to peptidoglycan or using the 
material in other ways in the cell, such as teichoic acid biosynthesis (Xia et al., 2010). There are several 
transglycosylases present in S. aureus that could still be active: PBP2, Sgt, MgtA, FtsW & RodA. However, if the 
transglycosylases were still assembling glycan chains that weren’t being crosslinked, residual incorporation of 
di-peptide would also be observed and is not. GlcNAc is also used for WTA synthesis, so residual incorporation 
may be explained by continued WTA biosynthesis after methicillin treatment.  
The combination of lack of incorporation and apparent continued cell wall hydrolysis suggests that weakening 
of the cell wall might play a role in cell death, possibly through the cell leakage described in Giesbrecht’s 
model. It has been shown that generalised lysis is not the cause of death in S. aureus after β-lactam treatment 
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(Foster, 1995). However, there are 19 putative hydrolases in S. aureus this redundancy means the cell wall 
could still be hydrolysed leading to breaches that allow cytoplasm to leak out, without generalised cell lysis. 
This also agrees with the fact that β-lactam killing is dependent on cells actively growing and studies have 
shown that hydrolysis is inhibited during stationary phase (Lioliou et al., 2016). Therefore, stationary phase 
cells could not be killed by β-lactams because they are not hydrolysing their cell wall. 
3.3.3. Action of cell wall antibiotics on B. subtilis 
 
B. subtilis was used as a comparator to S. aureus to begin to identify commonalities in the underlying 
mechanism of β-lactam killing. B. subtilis has a much lower MIC and dies much faster than S. aureus in the 
presence of methicillin. Some morphologies observed in NHS Ester labelled S. aureus were also visible in B. 
subtilis. There are some deformations at the septa of cells and many sacculi seem to have ripped open at a 
specific point, often the septum (Figure 3.18). Ripping at the septa and generally across the short axis of the 
cell corresponds to the weaker axis of the cell wall in B. subtilis (Beeby et al., 2013).  
An increase in cell length was not observed in B. subtilis, but a small increase in cell width was observed, 
whereas a significant increase in cell volume is observed in S. aureus under the same conditions (Figure 3.19). 
Some differences between B. subtilis and S. aureus peptidoglycan synthesis and structure could explain this. B. 
subtilis is a rod-shaped organism that grows through elongation followed by septation (Turner et al., 2014). 
Both organisms have very different glycan strand lengths, S. aureus glycan strands are on average 6 
disaccharides long, where B. subtilis glycan strands are several hundred or thousand disaccharides long 
(Hayhurst et al., 2008). With such long glycan chains, it may take much longer for hydrolysis of the chains to 
lead to a significant increase in cell length or width. This difference in glycan chain length combined with the 
rapid death of B. subtilis after treatment lead us to believe that a large increase in cell volume would not be 
observed in conditions that would show such an increase in S. aureus. 
These results indicate that B. subtilis may also be dying due to hydrolysis of the cell wall, leading to physical 
failure to maintain the turgor pressure. A more complete set of experiments would need to be completed in B. 







Vancomycin killing of S. aureus 
4.1. Introduction 
 
There are several different classes of antibiotics that target the cell wall. Fosfomycin and ᴅ-cycloserine both 
target the cytoplasmic steps of peptidoglycan production. Fosfomycin irreversibly inhibits MurA, leading to a 
reduction in peptidoglycan precursors (Bensen et al., 2012). Fosfomycin is the only antibiotic on the market to 
target a Mur-family protein. ᴅ-cycloserine is a structural analogue of ᴅ-alanine inhibiting the formation of ᴅ-
Ala-ᴅ-Ala, the terminus of the peptidoglycan side chain, leading to the accumulation of peptidoglycan 
precursors (Lambert & Neuhaus, 1972; Neuhaus & Lynch, 1964). Its neurological side effects mean it is used 
only as a second line drug against multidrug resistant infections (Nikolaidis et al., 2014). Beta-lactams and 
glycopeptides inhibit later steps of peptidoglycan assembly. Beta-lactams bind PBPs inhibiting their 
transpeptidase activity (Zapun et al., 2008). Glycopeptides non-covalently bind the ᴅ-Ala-ᴅ-Ala motif of the 
peptide side chains, inhibiting both transpeptidation and transglycosylation (Barna & Williams, 1984; Perkins, 
1969). Vancomycin was the first identified glycopeptide. In 2017, MRSA made up 16.9% of all S. aureus 
infections across the EU/EEA, with levels as high as 44.4% in some countries (“Surveillance of antimicrobial 
resistance in Europe 2017”). Glycopeptides are often the drug of choice to treat MRSA infections. However, in 
2002, the first vancomycin-resistant S. aureus (VRSA) isolate was reported in the USA. Due to the rise of VRSA, 
it is important that we better understand how glycopeptides kill S. aureus. A better understanding of the 
molecular pathways involved in cell death upon treatment with vancomycin can help identify targets for new 
drug development as well as better dosing regimens.  
Glycopeptides have been shown to bind secondary targets in the cell. It has been shown that certain 
glycopeptides (not vancomycin) bind directly to S. aureus PBP2 and cause some inhibition of peptidoglycan 
assembly through these secondary interactions (Leimkuhler et al., 2005). In S. aureus vancomycin binds the 
amidase unit of Atl, leading to an inhibition of hydrolase activity due to direct binding to the enzyme rather 
than only through steric hindrance due to binding of their substrate, peptidoglycan (Eirich et al., 2011). 
Many of the original studies on the mode of action of glycopeptides were done using the same techniques as 
were used to study beta-lactams: death kinetics, incorporation of radioactive compounds, culture turbidity 
(Kahne et al., 2005). Incorporation of 14C-labelled glutamic acid and glycine was used to study synthesis of new 
cell wall material after treatment with glycopeptides (Reynolds, 1961). This study showed an 80% decrease in 
incorporation of the radioactively labelled material within 20 minutes of treatment with 25 µg/mL vancomycin 
(10 x MIC for the strain used). The uptake of radioactively labelled amino acids into the protein fraction did not 
change in the first 40 minutes after treatment (Reynolds, 1961). The effect of vancomycin on 14C-GlcNAc and 
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14C-MurNAc-pentapeptide incorporation was also investigated in the 60s, yielding similar results and indicating 
that vancomycin inhibits cell wall synthesis (Anderson et al., 1965). 
There have been less in-depth studies into the molecular pathway to cell death after treatment with 
glycopeptides then with beta-lactams. Most of the more recent research surrounding glycopeptides has 
focused on resistance and tolerance. 
In this study, established and novel techniques were used to further investigate the mechanism of action of 
vancomycin. This enabled comparison to the bactericidal effect of methicillin as determined in Chapter 3. 
4.1.1. Aims of this chapter 
 
• Investigate the effect of vancomycin on S. aureus and B. subtilis 
• Establish death kinetics 
• Study the effect of vancomycin on cell morphology 
• Investigate the effects of vancomycin on macromolecular synthesis 
4.2. Results 
4.2.1. Killing Dynamics 
 
The MIC was determined by standard serial dilution method. The MIC of vancomycin against SH1000 was 4 
µg/mL. All experiments carried out with S. aureus SH1000 in this chapter were done using 10 x MIC, i.e. 40 
µg/mL vancomycin.  
A death curve of vancomycin against S. aureus SH1000 was done to determine death kinetics. The CFU/mL 
were determined at different time-points after addition of 10 x MIC vancomycin and the data was normalised 
by setting the first time point as 100%. A gradual killing of S. aureus SH1000 was observed over the 6 hours of 
treatment with vancomycin, with 90% killing reached after 6 hours (Figure 4.1). 
4.2.2. Cell morphology 
 
To investigate cell morphology, cells were treated with 10 x MIC vancomycin, fixed, labelled with NHS Ester 
555 and imaged using SIM. In the NHS Ester images of S. aureus SH1000 the only morphological change 
observed is an apparent increase in cell size (Figure 4.2). To quantify changes, the cell volume was measured 
using the ImageJ software and a method described by Zhou et al., 2015. A highly significant increase in cell 
volume was observed 15 minutes after addition of 10 x MIC vancomycin to the culture (Figure 4.3). After 30 

























Figure 4.1. Effect of 40 µg/mL (10 x MIC) vancomycin on S. aureus SH1000 cell viability. The CFU/mL was 
determined at each time-point and the data was normalised by setting the first time point as 100%. The mean 






Figure 4.2. Effect of vancomycin treatment on S. aureus SH1000 cell morphology (SIM images). Cells were 
treated with 40 µg/mL vancomycin (10 x MIC), fixed after 0, 30, 60 and 120 minutes treatment and 
subsequently labelled with NHS Ester 555. Cells were imaged using the OMX SIM and maximum intensity 
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Figure 4.3. Effect of vancomycin treatment on S.aureus SH1000 cell volume. Cell volume was calculated from 
measurements carried out in ImageJ, on OMX SIM images of NHS Ester 555 labelled cells at different time 
points after the addition of 40 µg/mL vancomycin (10 x MIC). P-values were calculated by Mann-Whitney tests. 
Whiskers extend from the minimum to the maximum values and boxes from the 25th to the 75th percentile. 






Figure 4.4. Effect of vancomycin treatment on SH1000 cell morphology (EM images). Cells were treated with 
40 µg/mL vancomycin (10 x MIC), fixed after 60 minutes of treatment and imaged by electron microscopy. All 
EM images were acquired by Lucia Lafage. (A) Fields of cells before antibiotic treatment. Scale bar 1 µm. (B) 
Fields of cells after 60 minutes of vancomycin treatment. Scale bar 1 µm. (C) Representative cell after 60 
minutes of treatment. Scale bar 200 nm. (D) Magnification of a cell section from a representative cell after 60 




To gain further insight, EM images of fixed S. aureus SH1000 cells were taken before and 60 minutes after 
treatment with 40 µg/mL vancomycin (Figure 4.4). In images of both samples, three morphologies were 
identified and their prevalence was quantified: cells with a complete septum, cells with an incomplete septum 
and cells with no visible septum (Figure 4.5). In the untreated sample, 58% of the cells don’t have a visible 
septum, 19% have an incomplete septum and 23% have a complete septum. After 60 minutes of treatment 
with 10 x MIC vancomycin 63% of the cells don’t have a visible septum, 17% have a complete septum and 20% 
have an incomplete septum. Unlike after methicillin treatment, no cells were observed with their cell 
membrane separated from the cell wall (Figure 4.4, Panel D). 
4.2.3. Quantification of peptidoglycan incorporation post-treatment 
 
Peptidoglycan incorporation was quantified using FDAA di-peptide and 14C-GlcNAc. Di-peptide incorporation is 
used as a measure of transpeptidase activity and 14C-GlcNAc incorporation is used as a measure of 
transglycosylase activity. 
In Figure 4.6, a decrease in di-peptide labelling of cells can be observed. The change in fluorescence/cell was 
quantified using Image J. The fluorescence per cell was measured for each cell and the background 
fluorescence was subtracted from this value. In the initial 5 minutes after addition of the antibiotic, a 
significant decrease (p < 0.0001) in labelling was observed (Figure 4.7). Within 15 minutes of vancomycin 
addition, only baseline levels of fluorescence were observed. 
Cells were incubated in the presence of 14C-GlcNAc for 5 minutes at different time-points after addition of 10 x 
MIC vancomycin. The cells were then fixed and the radioactivity of each sample was measured in 
disintegrations per minutes (DPM) per CFU. The data was corrected for CFU count because the number of cells 
60 minutes post-antibiotic treatment was smaller than in the control. A significant decrease (p = 0.0016) in 
incorporation was observed within 5 minutes of antibiotic addition (Figure 4.8). 14C-GlcNAc incorporation 
reached baseline levels within 5 minutes of antibiotic treatment. 
4.2.4. Fate of newly incorporated peptidoglycan 
 
S. aureus SH1000 was grown in the presence of ADA for 5 minutes before being washed and resuspended in 
ADA-free media and treated with 40 µg/mL (10 x MIC) vancomycin or not. The newly incorporated ADA was 
labelled with Alexa Fluor 594 by click chemistry. The cells were then labelled with NHS Ester 405 to 
contextualise the newly incorporated peptidoglycan (Figure 4.9). The aim of this experiment was to study the 
fate of newly incorporated material in an untreated vs. antibiotic treated population. 
The pattern of newly incorporated peptidoglycan observed depends on the stage of the cell cycle during which 




Figure 4.5. Quantification of cell morphologies in EM images after vancomycin treatment. In the EM images 
of the untreated sample and the sample treated with 40 µg/mL vancomycin (10 x MIC) for 60 minutes, three 
morphologies were identified and their prevalence was quantified. Quantification was carried out on a 




Figure 4.6. Effect of vancomycin treatment on di-peptide incorporation in S. aureus SH1000. Cells were 
grown in the presence of di-peptide for 5-minute periods after the addition of 40 µg/mL vancomycin (10 x 
MIC). The newly incorporated material was subsequently labelled by click reaction with atto 488 and imaged 
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Figure 4.7. Quantification of the effect of vancomycin treatment on di-peptide incorporation in S. aureus 
SH1000. Cells were treated with 40 µg/mL vancomycin (10 x MIC) and samples were incubated with di-peptide 
for 5 minutes at different intervals after antibiotic addition. Samples were then fixed and imaged using 
identical settings. The fluorescence/cell was measured using ImageJ. P-values calculated by Mann-Whitney. N 
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Figure 4.8. Effect of vancomycin treatment on S. aureus SH1000 incorporation of 14C- GlcNAc. Cells were 
treated with 40 µg/mL vancomycin (10 x MIC) and samples were incubated with 14C- GlcNAc for 5 minutes at 
different intervals after antibiotic addition. P-values calculated from unpaired t-tests with Welch’s correction. 






Figure 4.9. Fate of newly synthesised peptidoglycan after vancomycin treatment. Cells were grown in the 
presence of ADA for 5 minutes before being washed and treated with 40 µg/mL vancomycin (10 x MIC) or, for 
the untreated sample, being washed and resuspended in media without ADA. Cells were fixed at 0, 30 & 60 
minutes after addition of vancomycin or resuspension in fresh media. The incorporated ADA was clicked with 
Alexa Fluor 594 and the cells were labelled with NHS Ester 405. The data presented here was acquired 
simultaneously to the data presented in (Figure 3.14), the images for the untreated sample are therefore 
identical in both figures. (A) Fields of cells after 5 minutes of ADA incorporation. All scale bars 5 µm. (B) Fields 
of cells from the untreated and vancomycin samples 30 minutes after ADA incorporation. All scale bars 5 µm. 
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(C) Representative cells 30 minutes after ADA incorporation. All scale bars 1 µm. (D) Representative cells 30 
minutes after ADA incorporation and vancomycin addition. All scale bars 1 µm. (E) Fields of cells from the 
untreated and vancomycin samples 60 minutes after ADA incorporation. All scale bars 5 µm. (F) 
Representative cells 60 minutes after ADA incorporation. All scale bars 1 µm. (G) Representative cells 60 




an untreated cell population was discussed in 3.2.4.1. The cells progressed through the cell cycle in a normal 
manner and the localisation of the newly incorporated peptidoglycan changed accordingly.  
Six different morphologies were identified and the prevalence of each morphology was quantified at 0, 30 and 
60 minutes after washing and antibiotic addition (Figure 4.10).  
After 30 minutes of vancomycin treatment the newly incorporated peptidoglycan was located at the septum in 
56% of cells compared to < 10% of cells in the untreated sample. 33% of the treated cells had a split punctate 
pattern and 11% showed a whole cell pattern. After 60 minutes of treatment, there were only very small 
changes to the observed patterns and their rate of occurrence compared to 30 minutes after treatment 
(Figure 4.10).  
4.2.5. Action of vancomycin on B. subtilis 
4.2.5.1. Killing dynamics 
 
The MIC was determined by standard serial dilution method. The MIC of vancomycin against B. subtilis 168 HR 
is 0.25 µg/mL. All the experiments described in this chapter were done with 10 x MIC, i.e. 2.5 µg/mL 
vancomycin.  
A kill curve was carried out with vancomycin, measuring the CFU/mL present in the culture at regular intervals. 
B. subtilis 168 HR dies rapidly after vancomycin treatment. 90% killing was reached in the first 60 minutes after 
addition of 2.5 µg/mL vancomycin to the growth media (Figure 4.11).  
4.2.5.2. Morphological changes 
 
B. subtilis 168 HR was fixed at different time points after treatment with 2.5 µg/mL vancomycin and labelled 
with WGA 594 to visualise cell morphology (Figure 4.12). WGA was used for this experiment rather than NHS 
ester because NHS ester cytoplasmically labelled a large part of the population (data not shown). This problem 
did not occur with WGA. After treatment with vancomycin, cell deformations are observed in the septal area. 
After 15 minutes some wider deformed septa are visible. After 30 and 60 minutes of treatment, sacculi are 
visible in the sample. These appear to have always ripped across the width of the cell (Figure 4.12, Panel B).  
Cell length and width were measured on the WGA SIM images using ImageJ. There was no significant change in 
cell length after treatment with 2.5 µg/mL vancomycin for 60 minutes (Figure 4.13). There was a significant 
increase in cell width within 15 minutes of treatment with 10 x MIC vancomycin. The mean cell width of the 





Figure 4.10. Quantification of the effect vancomycin on the fate of newly synthesised peptidoglycan. Six 
different cell morphologies were identified, and representative cells are pictured. The prevalence of each 
morphology was quantified in a population of approx. 100 (n as indicated in graph) cells for every sample. 
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Figure 4.11. Vancomycin killing of B. subtilis. B. subtilis 168 HR was treated with 2.5 µg/mL vancomycin (10 x 
MIC). The CFU/mL was determined at each time-point and the data was normalised by setting the first time 




Figure 4.12. Effect of vancomycin on B. subtilis 168 HR morphology. Cells were treated with 2.5 µg/mL 
vancomycin (10 x MIC), fixed after 0, 15, 30 and 60 minutes of treatment and subsequently labelled with WGA 
594. Cells were imaged using the OMX SIM and maximum intensity projections are shown. (A) Fields of cells 
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from each time point, as indicated. All scale bars 5 µm. (B) Representative cell after 60 minutes of treatment. 
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Figure 4.13. The effect of vancomycin on B. subtilis 168 HR cell length and width. Cell length and width were 
measured in image J using images acquired on the OMX SIM of WGA labelled B. subtilis fixed at different time 
points after the addition of 2.5 µg/mL vancomycin (10 x MIC). The error bars represent standard deviation. P-




4.3. Discussion  
4.3.1. Morphological changes 
 
Vancomycin is bactericidal for S. aureus. In the images of S. aureus SH1000 labelled with NHS ester after 
treatment with 10 x MIC vancomycin, no gross morphological changes were observed. The cells appear to 
maintain their shape. A significant increase in cell size (p < 0.0001) was observed after 15 minutes of treatment 
with 40 µg/mL vancomycin (Figure 4.3). An increase in cell size could be due to cell wall synthesis and 
hydrolysis, which are both required for cell growth (Wheeler et al., 2015).  
S. aureus SH1000 cells imaged by EM after treatment with 10 x MIC vancomycin showed few morphological 
changes (Figure 4.4). Quantification of observed morphologies showed very little change between the control 
sample and the sample after 60 minutes of vancomycin treatment (Figure 4.5). Due to the lack of 
peptidoglycan synthesis, the cells are not progressing through the cell cycle, suggesting their morphology is 
fixed after treatment with vancomycin.  
Cell wall synthesis was studied by measuring 14C-GlcNAc incorporation and FDAA incorporation after 
vancomycin treatment (Figure 4.7 & Figure 4.8). The rapid decrease in transglycosylation and transpeptidation 
observed here agrees with some original studies into the mode of action of vancomycin. These studies looked 
at the incorporation of 14C-glutamic acid, noting an ~80% decrease in incorporation into the cell wall fraction 
after 20 minutes of incubation with 25 µg/mL vancomycin (Reynolds, 1961). This halt of incorporation suggests 
that the observed increase in cell size is not due to cell wall synthesis and is therefore likely due to cell wall 
hydrolysis. The glucosaminidase family of hydrolases is thought to play a crucial role in cell wall growth 
(Wheeler et al., 2015). Investigating mutants lacking members of the glucosaminidase family would give more 
insight into the cell size increase observed after vancomycin treatment.  
4.3.2. Fate of newly incorporated peptidoglycan 
 
After 5 minutes of ADA incorporation, the newly incorporated ADA is located at the septum in just over 80% of 
the cells, with 10% of the cells displaying a split punctate pattern and the last 10% showing no focus of 
incorporation (i.e. “whole cell” pattern) (Figure 4.9 & Figure 4.10). After 30 minutes of treatment with 40 
µg/mL vancomycin, an increase in the number of split punctate cells was seen, which is due to cells that had 
completed their septa during the 5 minutes of incorporation then dividing. This suggests hydrolases involved in 
cell division are still active after antibiotic treatment. However, cells are not progressing through the cell cycle 
due to the lack of peptidoglycan incorporation. There is very little change between 30 and 60 minutes, 
suggesting the cells have simply halted at whatever stage of the cell cycle they found themselves in when 
vancomycin was added to the growth culture.  
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4.3.3. Action of vancomycin on B. subtilis 
 
After treatment of B. subtilis 168 HR with vancomycin, we see very similar effects as after treatment with 
methicillin. The same ripping at the septa and across the short axis of the cell wall is observed (Figure 4.12 & 
Figure 3.18). This corresponds to the weaker axis of the B. subtilis cell wall (Beeby et al., 2013). The cells have 
not significantly increased in cell length but have increased significantly in width after treatment with 
vancomycin. In B. subtilis peptidoglycan is organised in long polysaccharide chains that run circumferentially 
around the short axis of the cells (Turner et al. , 2014). The glycan chains of B. subtilis are 50 - 5000 
disaccharides long compared to 6 - 12 disaccharides long in S. aureus. The long chains, their spatial 
organisation and the fact that killing happens rapidly, help explain why no significant increase in cell length is 
observed. An increase in cell length might require more hydrolysis than the amount required to observe an 









Investigating the role of cell wall metabolism in the bactericidal effect of antibiotics 
5.1. Introduction 
 
The S. aureus cell wall is composed of a lipid bilayer and a thick outer peptidoglycan layer (20-35 nm 
thick)(Schleifer & Kandler, 1972). Teichoic acids decorate the cell wall, with wall teichoic acids (WTA) anchored 
to the peptidoglycan layer and lipoteichoic acids (LTA) tethered to the cell membrane (Silhavy et al., 2010). Cell 
wall metabolism encompasses both peptidoglycan synthesis and hydrolysis, which together control the 
function of this essential polymer. 
Peptidoglycan synthesis begins in the cytoplasm with the assembly of lipid I and lipid II (Typas et al., 2012). 
Lipid II is flipped across the membrane before being polymerised into long glycan chains, which are then 
crosslinked. The action of hydrolases leads to further modification of the peptidoglycan, resulting in the final 
architecture of the cell wall (Wheeler et al., 2015). The S. aureus cell wall is smooth on the inside with very few 
small holes and has a looser mesh appearance with larger holes on the outside (Pasquina-Lemonche et al., 
unpublished).  
Previous data presented in Chapters 3 and 4 of this thesis showed that treatment of S. aureus SH1000 with 
methicillin or vancomycin lead to inhibition of peptidoglycan synthesis and changes in cell wall structure, 
leading to the investigation of other components of cell wall metabolism. After treatment with methicillin or 
vancomycin, an increase in cell size was observed despite a lack of peptidoglycan synthesis. In this chapter, the 
possibility of this cell size increase being due to the action of cell wall hydrolases is investigated.  
There are 20 putative hydrolases in S. aureus. Within this, glucosaminidase activity is essential for normal 
growth of bacteria as discussed in 1.6.1. The four putative glucosaminidases in S. aureus are essential as a 
group of enzymes and are mutually redundant (Wheeler et al., 2015). Peptidoglycan synthesised at the septum 
has long glycan strands which are cleaved by glucosaminidases, primarily SagB, leading to alterations in the 
biophysical properties of the cell wall. The action of the glucosaminidases results in S. aureus having short 
glycan strands with an average of 6 disaccharides (Boneca et al., 2000). The involvement of peptidoglycan 
hydrolases and cell structure and modification in the action of antibiotics is not well understood. Previous 
research has shown that generalised cell lysis is not the cause of cell death. The generalised cell lysis observed 
after β-lactam treatment is due to Atl (Foster, 1995). However, degradation of the cell wall by other hydrolases 
has not been investigated as a cause of cell death. 
After methicillin treatment changes to the septal region were observed and presented in chapter 3 of this 
thesis. The cell membrane and cell wall appear to separate. Additionally, residual GlcNAc incorporation was 
measured after methicillin treatment. As previously discussed in Chapter 3, the bulbous septa and residual 
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incorporation could be explained by the presence of excess WTA. The role of WTAs in killing by cell wall 
antibiotics was therefore investigated and results are presented in this chapter. 
5.1.1. Aims of this chapter 
 
• Establish the role of glucosaminidases in cell wall antibiotic killing of S. aureus 
• Investigate the role of wall teichoic acids in cell wall antibiotic killing of S. aureus 
5.2. Results 
5.2.1. The role of glucosaminidases in cell wall antibiotic killing of S. aureus 
 
To study the role that glucosaminidases play in the killing of S. aureus by vancomycin and methicillin, single 
mutants and multiple mutants were used. Strains each lacking one of the four putative glucosaminidases were 
used to study the role of individual glucosaminidases (S. aureus SH1000 sagB, S. aureus SH1000 sagA, S. aureus 
SH1000 scaH, S. aureus SH1000 atl). To study them as a group of enzymes, triple mutants were used (S. aureus 
SH1000 atl sagA sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 
atl sagB scaH). The glucosaminidases are essential as a group, a quadruple mutant is therefore not viable.  
5.2.1.1. Killing dynamics 
 
S. aureus SH1000 sagB, SH1000 atl, SH1000 sagA and SH1000 scaH were grown to early exponential phase 
(OD600 0.2-0.3) before addition of 40 µg/mL methicillin (10 x MIC) to the growth media. The CFU/mL was 
measured at regular intervals. No significant difference in killing was observed between the wild-type and any 
of the glucosaminidase single mutants 6 hours after addition of 10 x MIC methicillin (Figure 5.1). 
The same experiment was carried out with the four triple glucosaminidase mutants: S. aureus SH1000 atl sagA 
sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB scaH. 
No significant difference in killing was observed between the wild-type and any of the triple mutants 6 hours 
after addition of 40 µg/mL methicillin ( 
Figure 5.2. Effect of methicillin on the viability of triple glucosaminidase mutants. S. aureus SH1000 atl sagA 
sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB scaH 
were each treated with 40 µg/mL methicillin (10 x MIC). Each strain is plotted individually with the S. aureus 
SH1000 WT control done on the same day. The CFU/mL was determined at each time-point and the data 
was normalised by setting the first time point as 100%. The mean and standard deviation are plotted. Each 
experiment was done in triplicate. P-values were calculated by two-tailed t-test with Welsh’s correction.). 
For two of the triple mutants, there appears to be increased killing, although the results are not significant due 
to variability in the data. 
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The triple glucosaminidase mutants were treated with 40 µg/mL vancomycin (Figure 5.3). After 6 hours of 
treatment no significant change in killing compared to S. aureus SH1000 was observed for mutants S. aureus 
SH1000 atl sagA sagB, S. aureus SH1000 atl sagA scaH, and S. aureus SH1000 atl sagB scaH. A slightly 





Figure 5.1. Effect of methicillin on S. aureus glucosaminidase single mutant cell viability. S. aureus SH1000 
sagB, SH1000 atl, SH1000 sagA and SH1000 scaH were treated with 40 µg/mL methicillin. Each strain is plotted 
individually with the S. aureus SH1000 WT control done on the same day. The CFU/mL was determined at each 
time-point and the data was normalised by setting the first time point as 100%. The mean and standard 
deviation are plotted. Each experiment was done in triplicate. P-values were calculated by two-tailed t-test 
with Welsh’s correction. 
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Figure 5.2. Effect of methicillin on the viability of triple glucosaminidase mutants. S. aureus SH1000 atl sagA 
sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB scaH 
were each treated with 40 µg/mL methicillin (10 x MIC). Each strain is plotted individually with the S. aureus 
SH1000 WT control done on the same day. The CFU/mL was determined at each time-point and the data was 
normalised by setting the first time point as 100%. The mean and standard deviation are plotted. Each 
experiment was done in triplicate. P-values were calculated by two-tailed t-test with Welsh’s correction.  
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Figure 5.3. Effect of vancomycin on the viability of triple glucosaminidase mutants. S. aureus SH1000 atl sagA 
sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB scaH 
were each treated with 40 µg/mL vancomycin (10 x MIC). Each strain is plotted individually with the S. aureus 
SH1000 WT control done on the same day. The CFU/mL was determined at each time-point and the data was 
normalised by setting the first time point as 100%. The mean and standard deviation are plotted. Each 
experiment was done in triplicate. P-values were calculated by two-tailed t-test with Welsh’s correction.  
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5.2.1.2. Cell morphology 
 
Cell morphology was investigated by fixing cells 0 & 60 minutes after addition of the antibiotic to the growth 
media, labelling them with NHS ester 555 and imaging them using SIM, as described in previous chapters. 
S. aureus SH1000 sagB, SH1000 atl, SH1000 sagA and SH1000 scaH were treated with 40 µg/mL methicillin. An 
hour after treatment, no major changes to cell morphology, other than cell size, were observed (Figure 5.4). To 
quantify changes in cell size, the cell volume of 100 cells was measured using ImageJ as described by Zhou et 
al., 2015. The population cell volume increased significantly after 60 minutes of treatment with 40 µg/mL 
methicillin in all the single glucosaminidase mutants ( 
Figure 5.5), compared to before antibiotic treatment. However, the amount by which each mutant increased 
in size after antibiotic treatment is different. In S. aureus SH1000 WT the mean cell volume of the population 
increased by a factor of 2.5. This is decreased to an increase of a factor of 2.1 for S. aureus SH1000 atl, 1.8 for 
S. aureus SH1000 sagA, 1.7 for S. aureus SH1000 scaH and 1.4 for S. aureus SH1000 sagB. 
To investigate changes in cell morphology after antibiotic treatment in the glucosaminidase triple mutants, the 
same experiment was carried out as with the single mutants. Cells were fixed 0 & 60 minutes post addition of 
40 µg/mL methicillin to the growth media, then labelled with NHS ester 555 and imaged using SIM (Figure 5.6).  
After 60 minutes of treatment with 40 µg/mL methicillin, cell morphologies appeared similar to before 
treatment apart from changes to cell size (Figure 5.6). Changes in cell volume were quantified in Image J using 
a method described by Zhou et al., 2015. There was no significant increase in the population cell volume of S. 
aureus SH1000 atl sagA sagB (p= 0.3035). There was a significant increase in cell volume of S. aureus SH1000 
sagA sagB scaH (p = 0.0311), S. aureus SH1000 atl sagA scaH (p < 0.0001) and S. aureus SH1000 atl sagB scaH 
(p < 0.0001) ( 
Figure 5.7). Although they still show a significant increase in cell volume, S. aureus SH1000 atl sagB scaH mean 
cell volume increased by a factor of 1.3 after 60 minutes of methicillin treatment and S. aureus SH1000 sagA 
sagB scaH mean cell volume increased by a factor of 1.1 after 60 minutes of methicillin treatment, compared 
to an increase in mean cell volume by a factor of 2.5 in the wild-type. In S. aureus SH1000 atl sagA scaH the 
cell volume increased by a factor of 1.8 after 60 minutes of methicillin treatment. 
The triple glucosaminidase mutants were treated with 40 µg/mL vancomycin and the same experiment and 
analysis was carried out. All the data in this paragraph was acquired by Elizabeth Tatham. After 60 minutes of 
vancomycin treatment, no major changes to cell shape were observed apart from changes to cell size (Figure 
5.8). All four triple mutants significantly (p < 0.0001) increased in cell volume after 60 minutes of treatment 
with 40 µg/mL vancomycin ( 
Figure 5.9). The mean cell volume of all four triple glucosaminidase mutants increased by a factor of 1.2 after 
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vancomycin treatment, compared to an increase by a factor of 1.5 in the mean cell volume of S. aureus 




Figure 5.4. Effect of methicillin on single glucosaminidase mutant morphology. S. aureus SH1000 sagB, S. 
aureus SH1000 sagA, S. aureus SH1000 atl and S. aureus SH1000 scaH were treated with 40 µg/mL methicillin 
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(10 x MIC), fixed after 0 & 60 minutes of treatment and subsequently labelled with NHS ester 555. Cells were 
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Figure 5.5. Effect of methicillin on the cell volume of single glucosaminidase mutants. S. aureus SH1000 atl, S. 
aureus SH1000 sagA, S. aureus SH1000 scaH and S. aureus SH1000 sagB were each treated with 40 µg/mL 
methicillin, fixed at different time-points after antibiotic addition, labelled with NHS Ester 555 and imaged 
using the OMX SIM. Cell volume was calculated from measurements carried out in ImageJ on these images. P-
values were calculated by Mann-Whitney tests. Whiskers extend from the minimum to the maximum values 
and boxes from the 25th to the 75th percentile. The middle of the box is plotted at the median. The factor by 





Figure 5.6. Effect of methicillin on triple glucosaminidase mutant cell morphology. S. aureus SH1000 atl sagA 
sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB scaH 
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were treated with 40 µg/mL methicillin (10 x MIC), fixed after 0 & 60 minutes of treatment and subsequently 
labelled with NHS ester 555. Cells were imaged using the OMX SIM and maximum intensity projections are 
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Figure 5.7. Effect of methicillin on the cell volume of triple glucosaminidase mutants. S. aureus SH1000 atl 
sagA sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB 
scaH were each treated with 40 µg/mL methicillin, fixed at different time-points after antibiotic addition, 
labelled with NHS Ester 555 and imaged using SIM. Cell volume was calculated from measurements carried out 
in ImageJ on these images. P-values were calculated by two-tailed t-test with welsh’s correction. Whiskers 
extend from the minimum to the maximum values and boxes from the 25th to the 75th percentile. The middle 
of the box is plotted at the median. The factor by which each strain increases in cell volume after 60 minutes 




Figure 5.8. Effect of vancomycin on triple glucosaminidase mutant cell morphology. S. aureus SH1000 atl 
sagA sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB 
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scaH were treated with 40 µg/mL vancomycin (10 x MIC), fixed after 0 & 60 minutes of treatment and 
subsequently labelled with NHS ester 555. Cells were imaged using the OMX SIM and maximum intensity 
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Figure 5.9. Effect of vancomycin on the cell volume of triple glucosaminidase mutants. S. aureus SH1000 atl 
sagA sagB, S. aureus SH1000 atl sagA scaH, S. aureus SH1000 sagA sagB scaH and S. aureus SH1000 atl sagB 
scaH were each treated with 40 µg/mL vancomycin, fixed at different time-points after antibiotic addition, 
labelled with NHS Ester 555 and imaged using the OMX SIM. Cell volume was calculated from measurements 
carried out in ImageJ on these images. P-values were calculated by Mann-Whitney tests. Whiskers extend from 
the minimum to the maximum values and boxes from the 25th to the 75th percentile. The middle of the box is 




5.2.2. The role of wall teichoic acid in cell wall antibiotic killing of S. aureus 
 
After 60 minutes of treatment with 40 µg/mL methicillin, amorphous exoplasmic material was observed in EM 
images of S. aureus SH1000 (Figure 3.5). This morphology could be due to wall teichoic acids being made but 
not being correctly incorporated into the cell wall. To investigate this possibility experiments were done using 
S. aureus SH1000 tarO, which lacks WTAs. 
5.2.2.1. Growth dynamics 
 
The growth of S. aureus SH1000 tarO was compared to that of S. aureus SH1000. The culture was inoculated to 
an OD600 of 0.05 from overnight cultures. OD600 measurements were taken every hour for 6 hours. To measure 
the difference in growth, a growth rate was calculated for each strain using the following formula (Neidhardt 









 gives the generation time, i.e. amount of time required for one doubling of the population. 
Growth rate was calculated between 0.5 and 2 hours after inoculation of the culture. S. aureus SH1000 
generation was 29.1 minutes and S. aureus SH1000 tarO had a generation time of 38.7 minutes. S. aureus 
SH1000 tarO grows slower than the wild-type (Figure 5.10). 
5.2.2.2. Killing dynamics 
 
MICs were measured using a serial dilution method. Cultures were grown overnight in the presence of 
different concentrations of antibiotics. After 24 hours, the OD600 of the cultures was measured and the MIC 
determined. The MIC of methicillin against S. aureus SH1000 tarO was 4 µg/mL, and the MIC of vancomycin 
against S. aureus SH1000 tarO was 4 µg/mL. These MICs were identical to the wild-type MICs.  
The effect of methicillin and vancomycin on S. aureus SH1000 tarO viability was investigated by CFU/mL death 
curve. Cultures were inoculated to an OD600 of 0.05 and grown to an OD600 of 0.2-0.3 (early exponential), when 
the antibiotics were added. CFU/mL measurements were done every hour for 4 hours.  
90% killing of S. aureus SH1000 tarO was achieved within one hour of addition of 40 µg/mL methicillin to the 
growth media, compared to after 3 hours in the wild-type (Figure 5.11). By 4 hours, 99.9% killing of S. aureus 
SH1000 tarO was achieved, compared to just over 90% killing of the wild-type. S. aureus SH1000 tarO dies 
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Figure 5.10. Growth curve of S. aureus SH1000 tarO compared to the wild-type. OD600 measurements were 
carried out at different time-points. The mean and standard deviation are plotted. This experiment was done 
in triplicate.  
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Figure 5.11. Effect of methicillin and vancomycin on S. aureus SH1000 tarO cell viability. S. aureus SH1000 
tarO  and S. aureus SH1000 WT were treated with 40 µg/mL methicillin (10 x MIC) or 40 µg/mL vancomycin (10 
x MIC) or with both antibiotics. The CFU/mL was determined at each time-point and the data was normalised 
by setting the first time point as 100%. The mean and standard deviation are plotted. This experiment was 




When treated with 40 µg/mL vancomycin, 10% killing of S. aureus SH1000 tarO is achieved after 2 hours, 
compared to 4 hours for the wild-type. After 4 hours of treatment with vancomycin, S. aureus SH1000 tarO has 
died significantly faster (unpaired t-test: p = 0.0323) than S. aureus SH1000. 
S. aureus SH1000 tarO was then treated with 40 µg/mL methicillin and 40 µg/mL vancomycin. Both antibiotics 
were added at the same time. When treated with both antibiotics, killing of S. aureus SH1000 tarO is not 
significantly different (unpaired t-test: p = 0.4769) to when the strain is treated with vancomycin on its own.  
Killing of S. aureus SH1000 is similar when it is treated with methicillin alone, vancomycin alone and when it is 
treated with both antibiotics (Figure 5.11). Unpaired t-test were carried out on the different samples at 4 
hours: methicillin vs. vancomycin (p = 0.0984), vancomycin vs. vancomycin + methicillin (p = 0.7492), 
methicillin vs. vancomycin + methicillin (p = 0.1800). 
5.2.2.3. Cell morphology 
 
S. aureus SH1000 tarO was treated with 10 x MIC vancomycin or 10 x MIC methicillin and fixed at 0 or 60 
minutes post-treatment. The samples were labelled with NHS ester 555 and imaged using the OMX SIM. No 
large cell deformations were observed in the images after treatment with methicillin or vancomycin (Figure 
5.12). However, NHS ester provides poor quality labelling of S. aureus SH1000 tarO. This is likely due to WTA 
making up a large proportion of the amines of the cell surface, which are the binding sites for NHS ester.  
S. aureus SH1000 tarO cultures were treated with 40 µg/mL methicillin or 40 µg/mL vancomycin (10 x MIC) 
and fixed at 0 & 60 minutes post-treatment, before being imaged by EM. After 60 minutes of treatment with 
10 x MIC methicillin, the sample contained a large amount of cell sacculi (Figure 5.13, panel A). Some cells 
exhibited similar morphologies to the wild-type treated with 10 x MIC methicillin. The cell membrane and the 
cell wall were separated by amorphous exoplasmic material (Figure 5.13, panel B). When this occurred around 
a newly forming septa, the septa maintained its pointed V-shaped morphology. After treatment with 10 x MIC 
vancomycin no such morphological changes were observed (Figure 5.13, panel C).  
Four morphologies were identified in the EM images of the S. aureus SH1000 tarO samples: cells with no 
visible septum (no septum), cells with incomplete septa (incomplete septum), cells with a complete septum 
(complete septum), cells with an aberrant septum (aberrant septum) (Figure 5.14). In the control sample, 
48.5% of the cells have no visible septum, 21% have a complete septum and 30.5% have an incomplete 
septum. After 60 minutes of treatment with 10 x MIC methicillin, 48% of the cells have no visible septum, 16% 
have complete septa, 22% have incomplete septum and 14% have aberrant septa. Aberrant septa are not 
found in the control or vancomycin treated sampled, only after 60 minutes of methicillin treatment. After 60 




Figure 5.12. Effect of methicillin and vancomycin on S. aureus SH1000 tarO cell morphology (SIM images). S. 
aureus SH1000 tarO was treated with 40 µg/mL methicillin or 40 µg/mL vancomycin, fixed after 60 minutes of 
treatment, labelled with NHS ester 555 and imaged with the OMX SIM. Samples as indicated. Maximum 






Figure 5.13. Effect of methicillin and vancomycin on S. aureus SH1000 tarO cell morphology (EM images). S. 
aureus SH1000 tarO was treated with 40 µg/mL methicillin or 40 µg/mL vancomycin, fixed at 0 and 60 minutes 
after antibiotic addition and imaged by EM. (A) Fields of cells from each sample. Samples as indicated. The 
methicillin and vancomycin samples were fixed after 60 minutes of treatment. Scale bars 2 µm. (B) 
Representative cell after 60 minutes of methicillin treatment with 200 nm scale bar. Magnification of a cell 
section from a representative cell with 100 nm scale bar. (C) Representative cell after 60 minutes of 
vancomycin treatment with 200 nm scale bar. Magnification of a cell section from a representative cell with 










Figure 5.14. Quantification of cell morphologies in EM images after treatment of S. aureus SH1000 tarO with 
methicillin or vancomycin. S. aureus SH1000 tarO was treated with 40 µg/mL methicillin or 40 µg/mL 
vancomycin. Samples were fixed and imaged before treatment and 60 minutes after addition of the antibiotic. 
Four morphologies were identified in the EM images and the prevalence of each morphology was quantified in 





septa and 23% have incomplete septa. 65% of methicillin-treated cells exhibited separation of the cell 
membrane from the cell wall compared to 1% of the cells in the control and vancomycin-treated samples. 
5.2.2.4. Fate of newly incorporated peptidoglycan 
 
S. aureus SH1000 tarO cultures in early exponential phase (OD600 0.2-0.3) were incubated in the presence of 
ADA for 5 minutes before being washed and treated with 40 µg/mL methicillin, treated with 40 µg/mL 
vancomycin or not treated with any antibiotic. The cells were fixed 0, 30 & 60 minutes after they were 
resuspended in the presence or absence of antibiotic. After fixation, ADA was clicked with Atto 488 and the 
cells were labelled with WGA 594. Cells were labelled with WGA rather than NHS ester (used for the wild-type 
samples in previous chapters) because of the poor labelling of NHS ester in the absence of WTA on the cell 
surface (Figure 5.12). The samples were imaged using the OMX SIM (Figure 5.15). Six patterns of ADA 
incorporation were identified throughout the samples (Figure 5.16, panel A). The prevalence of each pattern 
was quantified for each time point. S. aureus SH1000 wild-type data was also included for comparison. 
After 5 minutes of ADA incorporation, the newly incorporated material was located at the septum in 80% of 
the cells (Figure 5.15 & Figure 5.16). The remaining 20% of the cells displayed a split-punctate (4%) or whole 
cell morphology (16%).  
In the untreated population, 30 minutes after ADA incorporation 43% of the population displayed a half-cell 
morphology, with the rest of the population displaying a range of morphologies (Figure 5.15 & Figure 5.16, 
panel B). No cells displayed a quarter cell morphology 30 minutes after incorporation. 60 minutes after ADA 
incorporation, 67% of the cell population displayed a quarter cell ADA pattern and the rest of the population 
was spread between half cell (13%), whole cell (10%), split punctate (8%) and split donut (1%) morphologies. 
After 30 minutes of treatment with 40 µg/mL methicillin, 66% of the S. aureus SH1000 tarO cell population 
displayed a “septum” ADA pattern (Figure 5.15 & Figure 5.16, panel C). The rest of the cell population 
displayed either split-punctate or whole cell patterns of ADA. This is a slight increase in the prevalence of split-
punctate pattern and a decrease in the septum pattern compared to the control. After 60 minutes of 
methicillin treatment, the observed morphologies and their prevalence within the cell population were almost 
identical to the control. No cells display a split-donut, quarter or half-cell ADA pattern after 30 or 60 minutes 
of treatment with 10 x MIC methicillin (Figure 5.16, panel C). 
30 minutes after S. aureus SH1000 tarO was treated with 40 µg/mL vancomycin, half the population still 
displayed a septum ADA pattern. 30% of the cells displayed a whole cell ADA pattern and the remaining 20% 
showed a split-punctate morphology (Figure 5.16, panel D). No changes in ADA patterns were observed 






Figure 5.15. Fate of newly synthesised peptidoglycan in S. aureus SH1000 tarO after methicillin or 
vancomycin treatment. Cells were grown in the presence of ADA for 5 minutes before being washed and 
treated with 40 µg/mL vancomycin or 40 µg/mL methicillin or not. Cells were fixed at 0, 30 & 60 minutes after 
addition of the antibiotic or resuspension in fresh media. The incorporated ADA was clicked with Atto 488 and 
the cells were labelled with WGA 594. Fields of cells are presented for each time point and antibiotic as 






Figure 5.16. Quantification of fate of newly synthesised material over 60 minutes. Cells were grown in the 
presence of ADA for 5 minutes before being washed and resuspended in media without ADA or treated with 
40 µg/mL methicillin or 40 µg/mL vancomycin. Cells were fixed 0, 30 & 60 minutes after resuspension. The 
incorporated ADA was clicked with Atto 488 and the cells were labelled with WGA 594. (A) Representative cells 
of each observed morphology. Maximum projection composite images are presented where cyan is ADA 
Clicked with Atto 488 and magenta is WGA 594. Scale bars 1 µm. (B) Quantification of fate of newly 
synthesised material over time in S. aureus SH1000 tarO. Wild-type data presented for comparison. (C) 
Quantification of fate of newly synthesised material over time in S. aureus SH1000 tarO after treatment with 
10 x MIC methicillin. Wild-type data presented for comparison. (D) Quantification of fate of newly synthesised 
material over time in S. aureus SH1000 tarO after treatment with 10 x MIC vancomycin. Wild-type data 




5.3.1. The role of glucosaminidases in cell wall killing of S. aureus 
 
The individual inactivation of each glucosaminidase encoding gene did not lead to significant changes in killing 
by vancomycin or methicillin. This indicates that none of the putative glucosaminidases in S. aureus SH1000 
are single handedly responsible for the killing of S. aureus SH1000 by methicillin or vancomycin. When triple 
glucosaminidase mutants were tested, no significant decrease in killing was observed either. This suggests that 
as a class of hydrolases, glucosaminidases are not solely responsible for death after treatment with 10 x MIC 
methicillin or 10 x MIC vancomycin.  
Cell volume increases significantly in all the single glucosaminidase mutants after treatment with 10 x MIC 
methicillin ( 
Figure 5.5). However, the cell volume increases by a smaller factor in all the single glucosaminidase mutants 
than in the wild-type. The smallest increase in cell size was observed in S. aureus SH1000 sagB, with a size 
increase, after 60 minutes of methicillin treatment, of 1.4 x compared to 2.5 x in the wild-type (Figure 5.17). 
This suggests all the glucosaminidases function in the observed increase in cell size after treatment with 
methicillin but that SagB has the leading role. This is supported by previous research, which shows that 
glucosaminidases, in particular SagB, are responsible for cell growth (Wheeler et al., 2015). The same applies 
to the triple glucosaminidase mutants. S. aureus SH1000 atl sagA scaH, the strain still containing the sagB 
gene, shows a bigger increase in cell size than the three triple mutants lacking SagB. All of the other strains 
also show a slight decrease in the amount of cell size increase observed after methicillin treatment compared 
to the wild-type. This supports the idea that SagB plays the biggest role out of all four putative 
glucosaminidases in the increase in cell size observed after treatment of S. aureus SH1000 with 10 x MIC 
methicillin. Atl, ScaH and SagA also have a role but are responsible for a smaller part of the observed increase 
in cell size after treatment with methicillin. 
After 60 minutes of treatment with vancomycin all the triple glucosaminidase mutants had increased in size 
less than the wild-type. All of the mutants increased in size by the same factor, suggesting that all four 
glucosaminidases play an equal role in the cell expansion observed after 60 minutes of vancomycin treatment.  
These results indicate that cell size increase is not the main reason for cell death. However, cell wall hydrolysis 
may still play a major role in cell death. Other hydrolases, although not involved in swelling of the cell, may be 
involved in weakening the cell wall, eventually leading to mechanical failure. Although no decrease in killing by 
methicillin or vancomycin is observed in the single or triple glucosaminidase mutants, hydrolases could still 
have a function in beta-lactam killing. There are 19 known hydrolases in S. aureus giving the organisms a large 
amount of redundancy (Frankel et al., 2011; Pourmand et al., 2006; Ramadurai & Jayaswal, 1997; Stapleton et 




Figure 5.17. Model of methicillin induced killing of S. aureus SH1000 sagB. The “life” circle represents the 
three main morphologies differentiating different stages of the life cycle. The “death” circle represents 
morphological changes that occur after methicillin treatment and are thought to be involved in cell death. 
After treatment with 10 x MIC methicillin S. aureus SH1000 sagB cells increase in volume by a factor of 1.4. 
This increase is represented to scale in the diagram. Irrelevant of the stage of the cell cycle, many cells will 
have the cell membrane pulled away from the cell wall and their cell wall will be hydrolysed by the remaining 
hydrolases. Any complete or incomplete septum present are hydrolysed into their two component halves. If 
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the septum was complete, this produces two daughter cells. If the septum was incomplete, an incomplete split 




5.3.2. The role of wall teichoic acid in the cell wall antibiotic killing of S. aureus 
 
The MIC of vancomycin and methicillin are the same for S. aureus SH1000 and S. aureus SH1000 tarO, so any 
observed differences in killing cannot be attributed to a change in MIC.  
The absence of wall teichoic acids leads to increased sensitivity of S. aureus to methicillin with 99.9% killing 
after 4 hours of treatment, compared to 90% killing in the wild-type (Figure 5.11). S. aureus SH1000 tarO also 
died faster after treatment with vancomycin, although the increase in killing rate between the mutant and the 
wild-type is less after vancomycin treatment than after methicillin treatment. Previous research has shown 
that modification or absence of WTAs can lead to increased sensitivity to autolysis. Two different mechanisms 
have been proposed to be involved: change in localisation of Atl and a decrease in peptidoglycan crosslinking 
(Atilano et al., 2010; Schlag et al., 2010). The difference in killing between S. aureus SH1000 and S. aureus 
SH1000 tarO after treatment with methicillin or vancomycin could be explained by increased sensitivity to cell 
wall hydrolysis.  
Treatment of S. aureus SH1000 tarO with both methicillin and vancomycin gave a rate of killing the same as 
after treatment with just vancomycin. This suggests that vancomycin could be inhibiting the process that is 
leading to the accelerated killing of S. aureus SH1000 tarO by methicillin. As discussed above we know that 
two different processes could be leading to increased sensitivity to hydrolysis and therefore quicker killing. 
Previous studies have shown that vancomycin binds directly to Atl, inhibiting its activity (Eirich et al., 2011). 
Inhibition of Atl by vancomycin would help explain why treatment of S. aureus SH1000 tarO with both 
vancomycin and methicillin shows a slower rate of killing than methicillin on its own. If reduced crosslinking, 
mislocalisation of Atl and increased sensitivity to Atl are responsible for increase methicillin killing of S. aureus 
SH1000 tarO, inhibition of Atl by vancomycin would reduce the amount of killing.  
The increased killing still observed after vancomycin or vancomycin and methicillin treatment of S. aureus 
SH1000 tarO compared to S. aureus SH1000 could be explained by increased sensitivity to other hydrolases in 
the cell due to the lack of WTA. Previous research shows that a lack of D-alanylation of WTA or absence of 
WTA have an effect on the activity of vancomycin and other antimicrobial peptides (Brown et al., 2012; Farha 
et al., 2013).  
In EM images of methicillin-treated S. aureus SH1000 over 20% of cells showed an “incomplete split septum” 
morphology (Figure 3.6). These are incomplete septa that have been hydrolysed into their two component 
halves after methicillin treatment. It is possible that this hydrolysis was carried out by Atl, which is known to 
be one of the hydrolases involved in splitting of the mature septum during cell division (Foster, 1995). Only 2% 
of the cells in the wild-type sample show a complete septum or an incomplete septum that hasn’t been split 
after 60 minutes of methicillin treatment. This is also likely due to the action of Atl and other cell division 
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hydrolases in the absence of peptidoglycan synthesis. In the EM images of S. aureus SH1000 tarO 16% of cells 
have a complete septum and 22% of the cells have an incomplete septum, which is not split (Figure 5.14). In S. 
aureus SH1000 only 1% of the cells have a complete septa after 60 minutes of methicillin treatment (Figure 
3.6). This suggests there is significantly less hydrolysis of the septal plate after methicillin treatment in S. 
aureus SH1000 tarO compared to S. aureus SH1000. This supports the hypothesis that Atl is mislocalised in the 
absence of WTA and is therefore no longer splitting the septal plate correctly. In vancomycin the morphologies 
have not changed in the mutant compared to the wild-type. This is because Atl will be inhibited by direct 
binding of vancomycin irrelevant of whether WTA are present or not.  
In the EM images of S. aureus SH1000 tarO the membrane pulled away from the cell wall in 65% of the cells 
after treatment with methicillin for 60 minutes compared to 17.4% of the cells in S. aureus SH1000. This 
suggests that this space is not filled with WTA as was hypothesised in chapter 3. Other teichoic acids, such as 
LTAs could be occupying this space, or it could simply be liquid filled space between the wall in the cell 
membrane after loss of turgor through leaking of the cytoplasm. The significant increase in the number of cells 
exhibiting this morphology after 60 minutes of treatment with methicillin in the cells lacking WTA compared to 
the wild-type is likely due to the increased rate of killing. S. aureus SH1000 tarO cells imaged after 60 minutes 
of methicillin treatment are likely to be further along in the killing process than S. aureus SH1000. Figure 5.18 
summarises the above data in a model of antibiotic killing of S. aureus SH1000 tarO. 
The fate of newly incorporated peptidoglycan was investigated in untreated, vancomycin-treated and 
methicillin-treated populations of S. aureus SH1000 tarO (Figure 5.16). To allow for easy comparison the 
equivalent S. aureus SH1000 data was included again in this chapter, it is first presented in Chapters 3 & 4.  
In the untreated S. aureus SH1000 tarO sample, we see progression through the cell cycle with the appearance 
of the same patterns of ADA as were seen in the wild-type. The patterns are present at slightly different 
proportions, which is likely due to the slower growth rate of S. aureus SH1000 tarO compared to S. aureus 
SH1000 and possible changes to hydrolase activity.  
After 60 minutes of methicillin treatment there is very little change in the observed patterns of ADA 
distribution across the cell compared to the control (before treatment). Approximately 80% of the cells still 
have the incorporated ADA at their septum, with the remaining cells either having just divided (split-punctate) 
or showing no distinct foci of ADA localisation (whole cell). After 60 minutes of treatment with 10 x MIC of 
methicillin S. aureus SH1000 showed an increase in the number of cells exhibiting a split punctate and whole 
cell pattern of ADA, suggesting that hydrolases were still allowing for cell division and hydrolysis of the 
incorporated material into a less distinct pattern. The absence of these changes in S. aureus SH1000 tarO 
corroborates the idea that wall teichoic acids play a role in the action of methicillin on S. aureus.  
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Treatment of S. aureus SH1000 tarO with 10 x MIC vancomycin led to results very similar to those seen after 
treatment of S. aureus SH1000 with vancomycin. In all the antibiotic treated samples we saw a halt in 
progression through the cell cycle, supporting what was observed in S. aureus SH1000. The difference between 
methicillin and vancomycin is likely due to the differences described earlier in this discussion. If mislocalisation 
of Atl through lack of WTA is the main reason for changes in the action of methicillin S. aureus SH1000 tarO vs. 
S. aureus SH1000, then the inhibition of Atl by vancomycin explains why the mutant and the wild-type behave 
in similar ways after treatment with vancomycin (Figure 5.18). 
All of the above results suggest that there are two sets of hydrolases involved in killing – those that hydrolyse 
the entire cell wall and those that act on the septal plate, mainly Atl. After methicillin treatment, the action of 
both of these sets of hydrolases leads to killing. After treatment with vancomycin, the action of hydrolases 




Figure 5.18. Model of vancomycin and methicillin induced killing of S. aureus SH1000 tarO. The “life” circle 
represents the three main morphologies differentiating different stages of the life cycle. The “death” circle 
represents morphological changes that occur after methicillin or vancomycin treatment and are thought to be 
involved in cell death. Cell volume of S. aureus SH1000 tarO was not quantified after antibiotic treatment, 
circle sizes are therefore not representative. After methicillin treatment, but not vancomycin treatment, the 
membrane appeared to have pulled away from the cell wall. In S. aureus SH1000 tarO, the complete and 
incomplete septa do not appear to have been hydrolysed into their two component halves. Treatment with 









This project was set within a wider body of research that encompasses a broad range of specialist technologies 
and fields. These coalesce to give a deeper understanding of the action of cell wall antibiotics. Thus, to come 
to overall conclusions, it is important to contextualise the presented research. 
6.1. Associated data  
 
The data presented in this section provides a brief overview of work carried out by other PhD students. Their 
data contributes to the model of cell wall antibiotic killing presented later in this discussion.  
6.1.1. The impact of cell wall antibiotics on peptidoglycan architecture 
 
The work presented here was carried out by Laia Pasquina, PhD student, University of Sheffield.  
Recent high resolution AFM has shed light on the structure of the S. aureus cell wall (Pasquina-Lemonche et 
al., n.d.; Turner et al., 2010). The ring and knobbly structures on the outside of the cell and the smooth interior 
of the cell wall were described. The presented data suggests that hydrolases play a role in the action of cell 
wall antibiotics. AFM is therefore an interesting tool to investigate potential changes to cell wall architecture 
after treatment. 
AFM was used after treatment of S. aureus with 40 µg/mL (10 x MIC) methicillin or vancomycin. Samples were 
grown and treated with methicillin or vancomycin using the same protocol as for the other imaging 
experiments presented in this thesis. Samples were collected at different times before and after antibiotic 
addition and boiled. Cells were then broken by FastPrep, and the sacculi were stripped of all teichoic acids 
using hydrofluoric acid (HF). To remove all proteins from the sacculi, SDS, DTT and pronase were used. The 
sacculi were then imaged in air and in liquid using AFM. 
Cell wall thickness was measured in control samples and after 60 minutes of antibiotic treatment. This data 
was acquired by imaging in air. A significant decrease in cell wall thickness was observed after treatment with 
vancomycin or methicillin (Figure 6.1). This thinning could be explained by the lack of peptidoglycan 
incorporation coupled with continued autolysis activity. The existing cell wall material gets thinner as it is 
hydrolysed and the cells increase in size after antibiotic treatment without additional synthesis. The thinning is 
more pronounced after methicillin treatment, which could explain the fact that cells have increased in size 




Figure 6.1. Changes to cell wall thickness after treatment with methicillin (meth) or vancomycin (vanc). 
Mean and standard deviation are plotted. P-values were calculated by unpaired t-test. N = 28. Data acquired 
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The inside of the sacculi were imaged in liquid and the number of pores/µm2 was quantified. A pore in the 
sacculi was counted as such if it crossed the entire depth of the peptidoglycan cell wall. A significant increase 
in the number of holes on the inside of sacculi was observed after 60 minutes of methicillin or vancomycin 
treatment (Figure 6.2). This suggests peptidoglycan hydrolase activity on the inside of the cell surface. Cell 
death may be due to holes developing such that cell membrane integrity can no longer be maintained leading 
to cytoplasmic leakage.  
6.1.2. Role of WalKR in cell wall antibiotic killing of S. aureus 
 
The data in this section was acquired by Lingyuan Kong, PhD Student, Xiamen University.  
The WalKR two-component signalling system is essential in S. aureus. A conditional mutant with an IPTG-
inducible walKR operon was used for this study. WalKR regulates nine putative cell wall hydrolases in S. aureus 
(Dubrac et al., 2007). In the presence of IPTG, the strain grows in the same way as the wild-type S. aureus 
SH1000. In the absence of IPTG, the mutant dies due to the absence of normal levels of peptidoglycan 
hydrolysis (Delaune et al., 2011).  
In the absence of IPTG, the strain lacking WalKR died faster that the wild-type strain treated with methicillin or 
vancomycin. Treatment with methicillin or vancomycin significantly decreased the amount of death observed 
3 hours after removal of IPTG in S. aureus SH1000 walKR (Figure 6.3 & Figure 6.4). This rescue could be 
explained by the inhibition of peptidoglycan synthesis by the antibiotics, correcting the imbalance between 
peptidoglycan synthesis and hydrolysis in the absence of the WalKR system. This supports the idea that 
treatment with methicillin or vancomycin changes the balance between peptidoglycan synthesis and 
hydrolysis (Table 6.1). 
6.2. Beta-lactams vs. vancomycin: similarities and differences 
 
14C-GlcNAc incorporation reaches baseline levels after 5 minutes of treatment with vancomycin, compared to 
significant amounts of residual incorporation after an hour of treatment with methicillin (Figure 3.11 & Figure 
4.8). The decrease in incorporation of FDAA is similar within the first 30 minutes after treatment with both 
antibiotics (Figure 3.9 & Figure 4.6). This suggests both antibiotics may have a different effect on 
transglycosylation but a similar impact on transpeptidase activity. β-lactams bind PBPs, but Mgt, SgtA, FtsW & 
RodA have been shown to have transglycosylase activity (Emami et al., 2017; Reed et al., 2011; Taguchi et al., 
2019). These are not currently known to be inhibited by beta-lactams and may therefore still be active and 
explain the residual 14C-GlcNAc incorporation. Vancomycin binds both the peptidoglycan precursors and 
product, and therefore is likely to hinder any transglycosylase activity as soon as it has bound the ᴅ-Ala-ᴅ-Ala 




Figure 6.2. Effect of methicillin and vancomycin on the number of pores present on the inside surface of 
sacculi. AFM images of the inside of sacculi. The number of pores/µm2 was quantified for 4 sections of sacculi 
per sample. Mean, standard deviation and individual sample values are plotted. P-values were calculated by 
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Figure 6.3. Effect of methicillin treatment on S. aureus SH1000 walKR viability in the presence and absence 
of IPTG. The initial data point was set to 1 to normalise the data. The experiment was done in triplicate. Mean 
and standard deviation are plotted. P-value calculated by unpaired t-test comparing the two 0mM IPTG 
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Figure 6.4. Effect of vancomycin on S. aureus SH1000 walKR viability in the presence of absence of IPTG. The 
initial data point for each sample was set to 1 to normalise the data. The experiment was done in triplicate. 
Mean and standard deviation are plotted. The p-value was calculated by unpaired t-test comparing the two 




 Synthesis Hydrolysis Life/Death 
S. aureus SH1000 + + LIFE 
S. aureus SH1000 + 
cell wall antibiotics 
- + DEATH 
S. aureus SH1000 
walKR (no IPTG) 
+ - DEATH 
S. aureus SH1000 
walKR (no IPTG) + 
cell wall antibiotics 
- - Stasis 




if glycan chains were being synthesised but not crosslinked, as they are present on lipid II. Only residual 14C-
GlcNAc and no residual FDAA incorporation are observed after 30 minutes of methicillin treatment. Another 
possibility is that vancomycin inhibits a different cellular process that requires GlcNAc and is not inhibited by 
methicillin treatment. GlcNAc is utilised in the first step of  WTA synthesis and vancomycin has been shown to 
inhibit WTA synthesis in S. aureus (Singh et al., 2017). 14C-GlcNAc incorporation studies in a mutant lacking 
WTA (S. aureus SH1000 tarO) would show whether WTA synthesis is responsible for the observed residual 
incorporation after methicillin treatment. 
After treatment with methicillin an amorphous exoplasmic material appears in between the peptidoglycan and 
the lipid bilayer in some cells (Figure 3.5). No such material is observed after treatment with vancomycin 
(Figure 4.4). This difference in the EM morphologies, also explains the difference between the NHS ester 
labelled images. After treatment with methicillin, cells with deformed septa are observed in the SIM images of 
NHS ester labelled S. aureus SH1000 (Figure 3.3). This is likely due to the NHS ester binding to and labelling the 
amorphous exoplasmic material or being “trapped” in between the cell membrane and cell wall, if this is 
simply empty space due to the cell membrane pulling away from the cell wall. After vancomycin treatment, 
such deformations are not observed in the SIM images of NHS ester labelled cells, which agrees with the 
differences observed by EM (Figure 4.2). As the nature of the amorphous exoplasmic material has not yet been 
identified, we cannot draw conclusions from this observation, but it may simply be a space created by 
plasmolysis due to loss of turgor. 
Quantification of cell morphologies after EM treatment revealed a difference in morphologies after 60 minutes 
of vancomycin or methicillin treatment. After 60 minutes of methicillin treatment only 1% of cells had a 
complete septum compared to 17% of the cells 60 minutes after vancomycin treatment (Figure 3.6). This 
difference suggests that cells with complete septa are still splitting into two daughter cells after methicillin but 
not vancomycin treatment. Atl is known to be amongst the main hydrolases involved in cell division and is 
known to be inhibited by vancomycin (Eirich et al., 2011). Inhibition of Atl after vancomycin but not methicillin 
is a possible explanation for the observed differences. This could also explain the difference in kill curve shape 
(Figure 3.1 & Figure 4.1). After β-lactam treatment there is a small increase in CFU/mL, which is not observed 
after vancomycin treatment. The increase is potentially due to cells with complete septa dividing into two 
daughter cells.  
The investigation into the fate of newly incorporated peptidoglycan after antibiotic treatment revealed that 
progression through the cell cycle was halted after both vancomycin and methicillin treatment (3.2.4.2 & 
4.2.4). 
Cells increased in volume by a factor of 2.5 after 60 minutes of methicillin treatment and only a factor of 1.7 
after 60 minutes of vancomycin treatment (3.2.2.1 & 4.2.2). The inhibition of Atl by vancomycin may also be 
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involved in this observed difference between the two drugs. Although Atl is active at the septum, it also carries 
out hydrolysis across the whole cell wall (Foster, 1995). This could also be due to inhibition of WTA synthesis 
after vancomycin treatment, leading to irregularities in WTA content in the cell wall after vancomycin 
treatment (Singh et al., 2017). There is also the intriguing possibility of unidentified interactions between 
vancomycin and other cell wall hydrolases.  
6.3. Model of beta-lactam and vancomycin killing of S. aureus 
 
We propose that β-lactam and vancomycin killing of S. aureus is achieved through similar mechanisms, with 
some important differences (Figure 6.5). Although different cell wall antibiotic classes affect the same cellular 
processes, our results have shown that there are differences in the run up to cell death after treatment with 
the two different drug classes. 
After β-lactam treatment, hydrolases that act across the cell wall and those at the septum are digesting the 
cell wall. The action of these hydrolases coupled with the lack of peptidoglycan synthesis leads to weakening 
of the cell wall and presumptive cell division with unfinished septa. Both are proposed to lead to cell death. 
The appearance of holes, of increasing number and size, in the cell wall is thought to eventually lead to an 
inability of the membrane to maintain turgor and cytoplasmic leakage with concomitant cell death.  
After vancomycin treatment evidence suggests that Atl action is inhibited. This inhibition is likely due to 
binding of vancomycin to the peptidoglycan and direct binding to and inhibition of Atl. The smaller number of 
hydrolases acting on the cell wall, after treatment with vancomycin compared to methicillin, explains the 
smaller increase in cell size observed. After vancomycin treatment the eventual formation of pores in the cell 
wall leads to cell death through cytoplasmic leakage. 
This model suggests that cell wall antibiotics kill through a simple imbalance between peptidoglycan synthesis 
and hydrolysis (Table 6.1). This model is also supported by the fact that cell wall antibiotics are not active 
against stationary phase cells and that hydrolase activity has been shown to be reduced during stationary 
phase (Lioliou et al., 2016). The exact manifestation of the imbalance between synthesis and hydrolysis is 
altered after treatment with different cell wall antibiotics (Figure 6.5).  
This model is further supported by evidence that increased hydrolase activity leads to increased sensitivity to 
β-lactams (Rice et al., 2003). In the case of vancomycin, VISA strains have been shown to have decreased 
autolysis activity, decreasing the number of hydrolases at work and slowing down the killing process (Cameron 
et al., 2016). 
6.3.1. Comparison to previous models 
 




Figure 6.5. Model of the effect of methicillin and vancomycin treatment on S. aureus SH1000. The “life” circle 
represents the three main morphologies cells transition through as they go through the cell cycle. The “death” 
circle represents the changes to cell morphology observed after treatment with methicillin (red) or 
vancomycin (blue), depending on which stage of the cell cycle the cell was in upon addition of the antibiotic. 
Increases in cell size after treatment are represented to scale. Independent of the cell cycle and antibiotic, cells 
increased in size after treatment and holes appeared in the cell wall. No matter the stage of the cell cycle at 
the time of treatment, cell size increased more after methicillin than vancomycin treatment and the cell 
membrane separated from the cell wall after methicillin treatment only. If a cell had an incomplete septum, 
the incomplete septum was hydrolysed into its two component parts with ensuing death after methicillin 
161 
 
treatment but not vancomycin treatment. If cells had a complete septum upon methicillin addition, cell 




cycle and died attempting to complete the second division cycle after antibiotic treatment (Giesbrecht et al., 
1998). His EM images also showed bulging areas in the septal region, but these were interpreted as 
peptidoglycan incorporated after treatment. Our images show that the septal plate is in fact still displaying a 
thin pointed morphology. The problem with this model is that it considers that peptidoglycan synthesis is still 
taking place. However, our data suggests that peptidoglycan synthesis is significantly inhibited within 15 
minutes of antibiotic addition (3.2.3 & 4.2.3). Giesbrecht was right to suggest that incorrect initiation of cell 
division could lead to cell death after β-lactam treatment. Cells with complete septa also finish their current 
division cycle by dividing into two daughter cells, whereas vancomycin treatment prevents any progression 
through the cell cycle. 
The futile cycle of peptidoglycan synthesis and hydrolysis shown by Thomas Bernhardt in E. coli is the most 
recently published comprehensive model of β-lactam killing (Cho et al., 2014). This model requires 
peptidoglycan synthesis as well as hydrolysis to be taking place. The data presented in this thesis shows that 
no incorporation of peptidoglycan precursors is taking place after S. aureus treatment with methicillin or 
vancomycin. The difference between the observed effects in E. coli and S. aureus is likely due to the absence of 
the Rod system in S. aureus, which is thought to be responsible for the futile cycle observed after mecillinam 
treatment of E. coli. 
The original models around β-lactam killing align best with the results presented in this thesis. These were 
based on the hypothesis that peptidoglycan crosslinking would be inhibited but that glycan chains were still 
assembled, creating a loose cell wall being hydrolysed and leading to cytoplasm leakage (Alexander Tomasz, 
1979). Although the details of the model proposed here differ, the overall concept of a weakened cell wall 
leading to localised failure is the same. 
6.4. Future directions 
 
Further experiments are required to elucidate the role of hydrolases in cell wall antibiotic killing of S. aureus. 
Studies in strains lacking different combinations of hydrolases will be required to find which hydrolases play 
the biggest role in killing after peptidoglycan synthesis is inhibited. The large redundancy in peptidoglycan 
hydrolases will make this work difficult, as well as the likely essentiality of different groups of hydrolases. 
Hydrolases can be categorised in three different ways, according to activity (bond specificity), regulation or 
localisation. Inhibiting hydrolases according to either of these different groups may allow for new insight into 
their role. 
The presented research brings to the forefront our limited understanding of hydrolase activity and control in S. 
aureus. There are 19 putative hydrolases in S. aureus, many of which have never been studied. WalKR is 
thought to positively regulate the transcription of 10 putative hydrolases. The putative hydrolases that are 
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most upregulated by WalKR have not been studied. Transcription of some of these is upregulated up to 15-fold 
by the WalKR system (Dubrac et al., 2007). Although an increase in RNA does not necessarily translate to an 
increase in protein, it would still be of interest to investigate these genes further. An initial investigation might 
involve measuring changes to protein levels to determine whether these mirror the reported changes in RNA. 
Deletion or inactivation of the genes encoding individual putative hydrolases and study of the ensuing strains 
would give us insight into their functions and the role they play in the cell wall metabolism. Further study of 
hydrolase regulation would also be of interest. 
To better understand the differences between vancomycin and β-lactams further investigation into the 
interlinked role of WTA and hydrolases is necessary. Studies in a double atl tarO mutant would confirm 
whether the difference in vancomycin and methicillin killing of S. aureus SH1000 tarO is indeed due to the 
action of Atl. If Atl is responsible for the difference between methicillin and vancomycin killing of S. aureus 
SH1000 tarO, it’s absence would lead to both antibiotics having the same killing dynamics.  
Previous research has shown that inhibition of WTA synthesis sensitises MRSA to β-lactam treatment (Lee et 
al., 2016). A number of compounds exist that inhibit wall teichoic acid synthesis, one of these is tunicamycin. 
No published data has investigated treatment of MSSA infections with WTA synthesis inhibitors. Researching 
possible synergistic interactions between cell wall antibiotics and WTA synthesis inhibitors could lead to 
interesting translational studies. 
Further research is required to understand how this model of cell wall antibiotic treatment can be generalised 
to a range of different organisms, particularly gram-negative, which were not studied here. 
Overall my work has established a simple, coarse grain model for the action of the most important set of 
clinically relevant antibiotics. This gives a framework to elucidate the complex molecular interactions that 
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